Excretion of urinary proteins as predictors of early posttransplantation complications and late renal allograft failure by Teppo, Anna-Maija
EXCRETION OF URINARY PROTEINS AS PREDICTORS
OF EARLY POSTTRANSPLANTATION COMPLICATIONS
AND LATE RENAL ALLOGRAFT FAILURE
Anna-Maija Teppo
Department of Medicine, Division of Nephrology,
Helsinki University Hospital, Helsinki, Finland
ACADEMIC DISSERTATION
To be presented by the permission of the Medical Faculty of the University of Helsinki,
for public examination in the auditorium ” Richard Faltin ”
of the Department of Surgery, Helsinki University Hospital,
Kasarmikatu 11–13, Helsinki, on January 28 th, 2005, at 12 o’clock noon.
Helsinki 2005
2Supervised by
Professor Carola Grönhagen-Riska
Department of Medicine
Helsinki University Hospital
Helsinki, Finland
and
Docent Eero Honkanen
Department of Medicine
Helsinki University Hospital
Helsinki, Finland
Reviewed by
Docent Aimo Harmoinen
Central Hospital of Savonlinna
Savonlinna, Finland
and
Professor Christer Holmberg
University of Helsinki and Hospital for Children and Adolescents,
Helsinki, Finland
Opponent
Docent Ole Wirta
Department of Medicine
Tampere University Hospital
Tampere, Finland
Yliopistopaino
Helsinki, 2005
3CONTENTS
List of original publications ...................................................................................... 6
Abbreviations ............................................................................................................ 7
Abstract ..................................................................................................................... 9
Introduction .............................................................................................................. 10
Review of the literature ............................................................................................ 11
Part 1. Acute allograft rejection .............................................................................. 11
1. General aspects ............................................................................................ 11
1.1. Definition ............................................................................................ 11
1.2. Incidence ............................................................................................. 11
1.3. Clinical and laboratory findings .......................................................... 12
1.4. Types of acute rejection ....................................................................... 12
1.5. Histological picture ............................................................................. 13
1.6. Immunological aspects ........................................................................ 13
1.7. Prevention and treatment ..................................................................... 14
2. Non-invasive markers of acute rejection ..................................................... 15
2.1. Markers of glomerular filtration rate ................................................... 15
2.2. Urinary excretion of low molecular weight proteins ........................... 16
2.3. Markers of renal injury ........................................................................ 17
2.4. Markers of immunological activation .................................................. 18
2.5. Adhesion molecules in acute allograft rejection .................................. 19
2.6. Markers of inflammation ..................................................................... 19
2.7. New tools to detect acute rejection ...................................................... 21
Part 2. Chronic allograft dysfunction ...................................................................... 22
1. General aspects ............................................................................................ 22
1.1. Definition and clinical picture ............................................................. 22
1.2. Incidence ............................................................................................. 22
1.3. Histological picture ............................................................................. 23
1.4. Immunological risk factors .................................................................. 24
1.5. Non-immunologic risk factors ............................................................. 25
1.6. The role of TGF-β ............................................................................... 26
2. Surrogate markers of chronic allograft dysfunction .................................... 27
2.1. Histological findings ........................................................................... 27
2.2. Graft function ...................................................................................... 28
2.3. Hypertension ....................................................................................... 28
2.4. Proteinuria ........................................................................................... 29
42.5. Hyperlipidemia .................................................................................... 30
2.6. α-SMA positive myofibroblasts as the predictor of CAD ................... 31
2.7. New tools to predict outcome of renal allograft .................................. 31
Aims of the study ...................................................................................................... 32
Patients and methods ................................................................................................ 33
1. Subjects ....................................................................................................... 33
2. Urines and sera ............................................................................................ 35
3. Methods ....................................................................................................... 36
Part 1. Acute allograft rejection ................................................................ 36
3.1. Diagnosis and treatment of rejection ................................................... 36
3.2. Immunosuppression ............................................................................. 36
Part 2. Chronic allograft dysfunction ........................................................ 36
3.3. The regular clinical control of the patients .......................................... 36
3.4. Definition of the deterioration of GFR ................................................ 37
3.5. Immunosuppression ............................................................................. 37
3.6. Assessment and treatment of hypertension.......................................... 37
3.7. Assessment of atherosclerotic/cardiovascular disease ......................... 37
3.8. Analysis of protocol biopsies and estimation of interstitial fibrosis .... 37
3.9. Causes of death .................................................................................... 38
3.10. Assays ................................................................................................ 38
4. Statistical analyses ....................................................................................... 39
Results ...................................................................................................................... 40
Part 1. Acute allograft rejection .............................................................................. 40
1. Incidence of early acute rejection episodes ................................................. 40
2. Urinary excretion of α1-microglobulin during first posttransplantation
weeks in renal transplant recipients with and without acute rejection ........ 40
3. Urinary IL-1β/IL-1ra ratio as the marker of acute rejection ........................ 41
4. Urinary excretion of sICAM-1 as the marker of acute rejection ................. 41
Part 2. Chronic allograft dysfunction ...................................................................... 41
1. The outcome of patients .............................................................................. 41
2. Histopathological changes in 6 month protocol biopsy as the marker of
graft outcome ............................................................................................... 43
3. The urinary excretion of PIIINP at 6 months from transplantation as the
marker of graft outcome .............................................................................. 44
4. The urinary excretion of TGF-β1 at 6 months from transplantation in
progressors, non-progressors and in the healthy subjects ............................ 45
5. The urinary excretion of α1-microglobulin at 6 months from
transplantation as the marker of graft outcome ........................................... 45
56. The urinary excretion of albumin at 6 months from transplantation as the
marker of graft outcome .............................................................................. 46
7. Serum concentration of CRP during post-biopsy follow-up as the marker
of  graft outcome ......................................................................................... 48
Discussion ................................................................................................................. 49
1. Urinary IL-1β/IL-1ra ratio as the indicator of acute rejection ..................... 49
2. Genetic aspects of the production of IL-1ra and of IL-1β ........................... 49
3. The possible role of imbalanced IL-1β/IL-1ra ratio in the development of
CAD ............................................................................................................ 50
4. Urinary excretion of α1-microglobulin in the follow-up of renal
transplanted patients .................................................................................... 50
4.1. Urinary α1M as the marker of ischemia-induced injury ...................... 50
4.2. Urinary α1M as the indicator of acute rejection .................................. 50
4.3. Urinary α1M as the predictor of graft outcome ................................... 50
5. Urinary amino-terminal propeptide of type III procollagen  (PIIINP) as the
indicator of CAD ......................................................................................... 52
6. Albuminuria as the indicator of CAD ......................................................... 53
7. Elevated  posttransplant serum  CRP indicates risk for CAD ..................... 53
8. CRP does not accumulate in the grafts with CAN ...................................... 54
9. Chronic inflammation and CAD ................................................................. 55
10. Strategies for the future ............................................................................... 56
Summary and conclusions ........................................................................................ 57
Acknowledgements .................................................................................................. 58
References ................................................................................................................ 59
6LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications, which will be referred to in the
text by Roman numerals (I – VI), and on some previously unpublished data.
I Teppo A-M, Honkanen E, Ahonen J, Grönhagen-Riska C. Changes of urinary α1-
microglobulin in the assessment of prognosis in renal transplant recipients. Trans-
plantation 2000; 70: 1154-1159
II Teppo A-M, Honkanen E, Ahonen J, Grönhagen-Riska C. Does increased urinary
interleukin-1 receptor antagonist/interleukin-1β ratio indicate good prognosis in
renal transplant recipients? Transplantation 1998; 66: 1009-1014
III Teppo A-M, von Willebrand E, Honkanen E, Ahonen J, Grönhagen-Riska C. Sol-
uble intercellular adhesion molecule-1 (sICAM-1) after kidney transplantation: the
origin and role of urinary sICAM-1? Transplantation 2001; 71: 1113-1119
IV Teppo A-M, Törnroth T, Honkanen E, Grönhagen-Riska C. Urinary amino-termi-
nal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in
renal transplant recipients. Transplantation 2003; 75: 2113-2119
V Teppo A-M, Honkanen E, Finne P, Törnroth T, Grönhagen-Riska C. Increased
urinary excretion of α1-microglobulin at 6 months after transplantation is associat-
ed with urinary excretion of transforming growth factor-β1 and indicates poor long-
term renal outcome. Transplantation 2004; 78: 719-724
VI Teppo A-M, Törnroth T, Honkanen E, Grönhagen-Riska C. Elevated serum C-
reactive protein associates with deterioration of renal function in transplant recip-
ients. Clin Nephrol 2003; 60: 248-256
The original publications are reproduced with permission of the copyright holders.
7ABBREVIATIONS
ACE Angiotensin converting enzyme
ACR Acute cellular rejection
ADBP Adenosine deaminase binding protein
AHR Acute humoral rejection
α-GST Alpha- glutathione-S- transferase
α1M Alpha1- microglobulin
ANOVA Analysis of variance
APC Antigen presenting cell
AR Acute rejection
AUC Incremental area under the curve
β2M Beta 2-microglobulin
BMI Body mass index
BSA Bovine serum albumin
CAD Chronic allograft dysfunction
CADI Chronic allograft damage index
CAN Chronic allograft nephropathy
C4d Durable fragment of complement component 4
Ci Interstitial fibrosis of cortical area
CMV Cytomegalovirus
CR Chronic rejection
CRP C-reactive protein
CsA Cyclosporine A
CV Coefficient of variation
CVR Chronic vascular rejection
DSA Donor specific antibody
DTPA Diethylene triamine pentaacetic acid
ECG Electrocardiogram
ECM Extracellular matrix
EDTA Ethylenediaminetetraacetic acid
EIA Enzyme immunoassay
FBP Fructose-1,6-bisphosphatase
FN Fibronectin
GFR Glomerular filtration rate
GHbA1c Glycated hemoglobin
GST Glutathione-S-transferase
HLA Human leukocyte antigen
ICAM-1 Intercellular adhesion molecule-1
IFN-χ Interferon gamma
IL Interleukin
8IL-1ra Interleukin-1 receptor antagonist
IL-2R Interleukin-2 receptor
IR Insulin resistance
kD Kilodalton
LAP Latency associated protein
LDL Low density lipoprotein
LMW Low molecular weight
MAC Membrane attack complex
MCP-1 Monocyte chemoattractant protein-1
MHC Major histocompatibility complex
MP Methylprednisolone
mRNA Messenger RNA
NAG N-acetyl-β-D-glucosaminidase
OKT 3 Monoclonal antibody to CD3-complex on T cells
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
PDGF Platelet-derived growth factor
π-GST Pi-glutathione-S- transferase
PK Pyruvate kinase
PIIINP Amino-terminal propeptide of type III collagen
PTH Parathyroid hormone
RIA Radioimmunoassay
RPM Round per minute
RT Reverse transcription
SAA Serum amyloid A
SD Standard deviation
SDS Sodium dodecyl sulphate
sICAM-1 Soluble intercellular adhesion molecule-1
SMA Smooth muscle actin
sVCAM-1 Soluble vascular cell adhesion molecule-1
TGF-β Transforming growth factor-beta
TNF-α Tumour necrosis factor-alpha
TRIS Trishydroxymethylaminomethane
UA Urinary antigen
9ABSTRACT
Acute graft rejection (AR) and chronic allograft dysfunction (CAD) are the two most
common causes of renal transplant failure. Their early detection is crucial for the ade-
quate treatment and outcome.
In order to find out noninvasive markers of AR or other early posttransplantation compli-
cations and potential indicators of the developing of CAD, urinary excretions of α1M, IL-
1β, IL-1ra and sICAM-1 were measured in 137 renal graft recipients within the first post-
transplantation month, and urinary excretions of PIIINP, TGF-β1, a1M, albumin and se-
rum C-reactive protein in 79 graft patients at six months after transplantation. The histo-
logical findings in six month protocol biopsies were recorded. The patients were fol-
lowed up to 8.2 (mean 5.9) years.
During the first posttransplantation month 30 patients had AR, whereas 106 patients did
not show any signs of rejection. In patients with AR, urinary α1M/creatinine and IL-1β/
IL-1ra ratios increased a few days before rejection, whereas in patients with stable graft
function urinary α1M/creatinine ratio decreased and IL-1β/IL-1ra ratio remained un-
changed. During the follow-up period, GFR deteriorated in 21 patients (progressors), and
improved or remained the same in 58 patients. At six month from transplantation, the
mean protein/creatinine ratios of PIIINP (220 vs. 102 ng/mmol), TGF-β1 (107 vs. 45 ng/
mmol), albumin (60 vs. 5.4 mg/mmol) and serum concentration of CRP (5.3 vs. 1.4 mg/l)
were significantly higher in progressors than in those who preserved good graft function.
Urinary excretion of PIIINP associated with the extent of interstitial fibrosis and the ex-
cretions of TGF-β1 and α1M. During follow-up, GFR deteriorated in 60% of patients
with high α1M/creatinine ratio (> 5 mg/mmol), but only in 2% of patients with low ratio
(p< 0.01). The intraindividual baseline concentration of CRP remained constant for the
whole follow-up period and correlated inversely with the annual change of GFR (r=-
0.688, p<0.01).
In conclusion, high production of IL-1ra has a protective role after kidney transplantation
and regular measurement of urinary α1M and PIIINP provides a noninvasive means to
detect disturbances in the graft function and ongoing renal fibrosis. Low or decreasing
α1M/creatinine and PIIINP/creatinine ratios in consequtively collected urine samples to-
gether with normal serum concentration of CRP (< 1.7 mg/l) indicate good prognosis,
whereas increased ratios and elevated CRP predict poor long-term outcome.
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INTRODUCTION
The transplanted kidney is exposed to different forms of injury that result in tissue dam-
age. Acute graft rejection (AR) is a frequent cause of early injuries. Up to 50% of all
transplanted kidneys experience at least one AR episode. Most of these episodes are
asymptomatic and occur during the first three to six months after transplantation. Due to
modern immunosuppressive medication, more than 90% of the transplanted kidneys still
function well after the first year. Thereafter, about 4% of the cadaveric grafts are annually
lost. The single most prevalent cause of renal transplant failure is chronic allograft dys-
function (CAD) that is characterized by progressive deterioration of renal function and
excessive kidney fibrosis and sclerosis. The occurrence of AR episodes have been shown
to associate with the development of CAD. All grafts that develop CAD have undergone
previous tissue injury. Recent findings suggest that continuing or repetitive tissue injuries
or impaired repair from injury results in increased renal fibrosis and in the development
of CAD.
The early detection of injuries and the follow-up of tissue response and recovery from
injury is crucial for the adequate treatment and outcome. At present, histological exami-
nation of the allograft biopsies is the standard test for the diagnosis of AR and of CAD,
and the histological findings of the protocol biopsies are regarded as the most reliable
indicators of the developing of CAD and of poor graft prognosis. The invasive nature of
biopsy, however, restrain recurrent biopsies and limit their use in the follow-up.
This study was conducted to find out noninvasive markers of early posttransplantation
complications, and potential indicators for the development of CAD, which could be
helpful in selecting patients for more aggressive treatment and in evaluating the efficien-
cy of treatment. Urine was chosen as the main topic of this study for several reasons:
collection of urine is noninvasive, safe, minimally discomfortable, and there are no col-
lection restraints. In addition, urine may reflect the events in the graft more accurately
than biopsy or serum.
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REVIEW OF THE LITERATURE
Part 1. Acute allograft rejection (AR)
1. General aspects of acute allograft rejection
1.1. Definition
Acute graft rejection is defined as an immune response against donor antigens. It induces
and mediates functional and structural deterioration of the graft and is independent of
non-immunologic causes of renal dysfunction. It usually occurs within weeks to months
of transplantation. Histological criteria for diagnosis of AR include lymphocyte infiltra-
tion in association with tissue injury.
1.2. Incidence and timing
The recent immunosuppressive regimens have progressively reduced the incidence of
clinical acute rejections (First 2003). Still, at least one episode of clinical and/or histolog-
ical acute rejection occurs in 40-50% of cadaver kidney allograft recipients (Halloran et
al. 1997, 1999, Lobo et al. 1995, Campbell et al. 1998, Hariharan et al. 2000, Kahan
2000, Crespo et al. 2001, Pascual et al. 2002). More than half of the rejection episodes
occur within the first 30 days, and almost 90% occur in the first 3-6 months postransplant,
but they may occur much later (Gaber et al. 1998). Acute rejection episodes have been
documented as late as in the third decade after transplantation. About 35% of all acute
rejections are steroid resistant and account for the majority of graft losses during the first
posttransplantation year (Basadonna et al. 1993, van Saase et al. 1995, Gaber et al. 1998).
The 6-month and 12-month incidences of acute rejection were 37 and 43% in patients
treated with corticosteroids, azathioprine and ciclosporin microemulsion, and 20% and
24% in those treated with corticosteroids, azathioprine and tacrolimus (Mayer et al. 1997,
Margreiter 2002). In  studies with tacrolimus in combination with azathioprine or myco-
phenolate mofetil the 3-month incidence of acute rejection varied from 11 to 13% (Conwa
et al. 2002), and the 12-month incidence from 15 to 20% (Johnson et al. 2000).
In biopsies of patients with good graft function performed at 1 week (Jain et al. 2000 a,
Shapiro et al. 2001) or at 3 months (Seron et al. 1997, Legendre et al. 1998, Rush et al.
1994, 1998 b, Jain et al. 2000 a) after transplantation, borderline changes of acute rejec-
tion were detected in 46 to 87% of patients (Rush et al. 1998 b, Legendre et al. 1998,
Shapiro et al. 2001), whereas other groups found them only  in 12 to 28% of patients
(Seron et al. 1997, Jain et al. 2000 a). Rush et al. (1994) reported that more than 50% of
rejection episodes are subclinical and histologically as severe as those associated with
increases in serum creatinine.
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1.3. Clinical and laboratory findings
Previously, acute allograft rejection was clinically characterized by fever, malaise, re-
duced diuresis, increased body weight, hypertension, and by allograft tenderness or en-
largement. Nonselective proteinuria, sodium wasting in the urine, and tubular acidosis
could also been seen (Merrill 1971). These symptoms were characteristic to acute rejection
but none of them was specific. Nowadays many patients, especially those treated with cy-
closporine, can be relatively asymptomatic during acute rejection episodes ( Cohen et al.
1988, Gaber et al. 1998). Gaber et al. (1998) reported that approximately 14% of patients
with acute rejection episode had decreased urine volume, and 17% had fever. In spite of the
lack of clinical symptoms, one third of renal graft recipients with stable graft function show
unsuspected subclinical rejection at 6 month protocol biopsy (Rush et al. 1994, Seron et al.
1997, Legendre et al. 1998, Nickerson et al. 1998, Veronese et al. 2002).
At present, the diagnosis of AR is based on clinical evidence of graft dysfunction, and
histological examination of fine-needle aspiration samples (Pasternack et al. 1973) or
core biopsy. The serial measurement of serum creatinine is used to follow the changes of
graft function. An increase of serum creatinine by about 20% from  baseline is often
regarded as a signal for further evaluation. In some cases, examination of  graft tissue or
urine for evidence of inflammation and tissue injury, or tests identifying the activation of
immune system have been included.
1.4. Types of acute rejection
Acute cellular rejections (ACR)  usually comprise more than 80% of all acute rejections
(Halloran et al. 1992, Salmela et al. 1992, Lobo et al. 1995, Campbell et al. 1998, Crespo
et al. 2001). It responds well to high doses of steroids and its prognosis is good, one-year
graft survival usually exceeding  90% (Feucht et al. 1993, Lobo et al. 1995, Kooijmans-
Coutinho et al. 1996).
The production of donor-specific antibodies agains a transplanted organ leads to humoral
or alloantibody-mediated acute rejection (AHR) (Jeannet et al. 1970, Halloran et al. 1992,
Trpkov et al. 1996) and activation of complement (Collins et al. 1999). AHR comprises
5-10% of all acute rejections (Lobo et al. 1995, Campbell et al. 1998, Crespo et al. 2000).
It is characterized by prominent allograft dysfunction, typically occurs early after trans-
plantation, often in retransplants, and is resistant to steroid treatment, and often leads to
severe graft injury. The risk for graft loss is high, with reported one year graft survival
rate varying between 15 and 57% (Halloran et al. 1992, Feucht et al. 1993, Lobo et al.
1995, Campbell et al. 1998, Pascual et al. 2002). More than one third of patients with
steroid resistant AR have evidence of AHR (Crespo et al. 2001). Although the immediate
risk for graft loss due to AHR is high, the patients who recover from AHR episode have
a similar long-term graft outcome than patients without it (Feucht and Opelz 1996, Camp-
bell et al. 1998).
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The term acute vascular rejection has been used to describe AR with prominent vascular
features (Salmela et al. 1992, Kooijmans-Coutinho et al. 1996, Crespo et al. 2000) that
can include both antibody- and T-cell mediated features and has been suggested to have a
greater propensity for CAD than other ARs. Van Saase et al. (1995) reported 5-year graft
survival rate to be only 34% in patients with early vascular rejection, and 71% in those
with cellular rejection.
1.5. Histological picture
Acute rejection is characterized by an influx of inflammatory cells, especially monocytes
and lymphocytes, into the allograft and by a cascade of cytokine-cell interactions within
the graft (Solez et al. 1993). The diagnosis of AR is done on the basis of tubulitis, intimal
arteritis, interstitial inflammation, and of glomerulitis. The severity of rejection is deter-
mined by grading each of these parameters according to the criteria of the Banff 97 work-
ing classification (Racusen et al. 1999). Tubulitis and intimal arterities are the basic fea-
tures for the rejection classification.
There is no significant histological difference between ACR and AHR. Tubulitis and
endothelitis are characteristic for ACR, whereas neutrophils in peritubular capillaries,
vasculitis, arteritis with fibroid necrosis, and microthrombi in arterioles and glomeruli are
suspicious to AHR. At present, diagnosis of AHR is based on identification of suspicious
morphological features on biopsy, confirmation of circulating antibodies against donor
antigens, and on staining of complement activation product C4d in the peritubular capil-
laries of the graft (Feucht et al. 1991, 1993, Collins et al. 1999, Böhmig et al. 2002,
Watschinger and Pascual 2002, Magil and Tinckam 2003). C4d binds covalently to tissue
(Zwirner et al. 1989) and can therefore be detected by immunochemical stainings in the
biopsies taken a long time after AHR. C4d was found in 45% of early dysfunctioning
grafts (Feucht et al. 1993).
1.6. Immunological aspects
The donor antigens present in the graft result in the immunological response. In ACR,
the major histocompatibility complex (MHC) antigens initiate the immune activation ei-
ther directly or indirectly. In the direct activation, the contact of donor antigens or donor
antigen-presenting cells (APCs) with the resident’s T-cells results in an intense immune
response in the early posttransplant period. This response fades away simultaneously
with the disappearance of donor APCs from the graft.
In the indirect activation, recipient APCs introduce the donor MHC-derived peptides to
the recipients T-cells. The contact of these foreign peptides with T-cell receptor activates
T-cells, and results in increased production of cytokines and increased number of T-cells.
The cytokines released from the T-cells induce on the endothelium the expression of
adhesion molecules, which bind leukocytes and facilitate the infiltration of lymphocytes
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into the graft. The products of activated lymphocytes together with the graft infiltrating
cells result in increased expression of class I and II MHC antigens on endothelial cells
and in more vigorous immune response.
In AHR, the antibodies produced against donor antigens (DSA) can damage allografts
through the activation of complement and the deposition of membrane attack complex
(MAC). This results in the activation of endothelial cells, macrophages and platelets that
in turn results in increased adhesion, chemotaxis, and coagulation (Baldwin et al. 1999).
1.7. Prevention and treatment of acute rejection
Due to the crucial role of T-cells in the initiation and coordination of the immune re-
sponse, the currently used immunosuppressive drugs are targeted on the various steps of
T-cell activation. In the immediate post-transplant period when the risk of graft rejection
is the greatest, immunosuppression is best achieved with a combination of drugs. Com-
monly used triple therapy consists of azathioprine, cyclosporin A and methylprednisolon.
Antiproliferative agents (azathioprine or mycophenolate) prevent the expansion of acti-
vated T- and B-cells, calcineurin inhibitors (cyclosporin or tacrolimus) prevent interleukin-
2 gene transcription and thus inhibit interleukin-2 production by T-cells, and corticoster-
oids are used as non-specific anti-inflammatory agents.They inhibit cytokine production
of T-cells and macrophages, intercept T-cell activation and thus prevent macrophage-
mediated tissue injury.
Individuals at higher risk for acute rejection may receive additional administration of
potent anti-T-cell antibody preparations such as OKT3, Daclizumab or Basiliximab. Since
these agents are targeted on all T-cells, they lack specificity and their use has been accom-
panied by reduced response to malignant diseases and infections. Some immunosuppres-
sive agents have side effects such as hypertension or nephrotoxicity, and some have been
implicated in the pathogenesis of CAD.  The new immunosuppressive strategies focus on
inhibition specifically on only those T-cells that respond to donor antigens. The mono-
clonal antibodies which block interactions either between T-cells and the antigen-pre-
senting cells (Denton et al. 1999) or between  endothelial cells and adhesion molecules
(Haug et al. 1993, Hourmant et al. 1996) have been successfully used. Gene therapy may
offer an ideal means to deliver inhibitory or protective agents specifically into the graft
(Platt 1997, Imai and Isaka 2004). Clinical application of gene therapy is promising (Imai
and Isaka 2004).
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2. Non-invasive markers of acute rejection
2.1. Markers of glomerular filtration rate (GFR)
In the clinic, allograft function is monitored by serial measurements of serum creatinine
concentration. The test is rapid and cheap but unsensitive. Up to 50% reduction of glomer-
ular filtration rate (GFR) is often associated with still normal serum creatinine levels.
Moreover, the results are affected by age, sex, muscle mass, physical activity, diet and
tubular creatinine secretion (Perrone et al. 1992). In patients with slightly reduced GFR
serum creatinine often overestimates it. Therefore there has been an ongoing search for
suitable alternative markers of GFR.
As many small molecular weight proteins such as α1- and β2-microglobulins and cystatin
C are excreted almost exclusively through glomerular filtration, their serum concentra-
tions can be used as the marker of GFR. Serum β2-microglobulin (β2M) has been exten-
sively measured in renal transplanted patients (Wibell et al. 1973, Shea et al. 1981, Schar-
din and van Eps 1987). High pretransplantation serum levels of β2M have been reported
to decline toward normal at varying rates after successful renal transplantation (Bernier
and Post 1973, Edwards et al. 1983). Constantly high or increasing serum β2M have
shown to predict clinical rejection by several days (Edwards et al. 1983, Maury and Tep-
po 1984, Bäckman et al. 1986, Prischl et al. 1989). The increase of serum β2M is not,
however, specific for acute rejection but may be associated with cyclosporine toxicity
(Bäckman et al. 1986 ), bacterial, viral and fungal infections (Vincent et al. 1979, Maury
and Teppo 1984, Bäckman et al. 1986, Prischl et al. 1989) and with the deterioration of
GFR due to other causes (Maury and Teppo 1984, Schardin and van Eps 1987). Bäckman
et al. 1986 reported serum β2M to be unable to distinguish between AR and cyclosporine
toxicity, but suggested it to be helpful in the early detection of CMV infection.
Cystatin C is a 13 kD molecular weight, non-glycosylated protein that is produced by all
nucleated cells and eliminated from blood by glomerular filtration. Its production rate is
constant and it is unaffected by inflammatory processes, abnormal tissue growth, muscle
mass, sex, age, diet or nutritional status (Uhlmann et al. 2001, Leach et al. 2002). A single
reference value can be used for children and adults of both sexes. A single measurement
of serum cystatin C provides a precise and accurate estimation of GFR (Larsson et al.
2004). During the first four posttransplant days, cystatin C decreases more rapidly than
serum creatinine. In the immediate posttransplant period, cystatin C may thus detect graft
dysfunction and its recovery more rapidly than serum creatinine (LeBricon et al. 1999,
Leach et al. 2002, Christensson et al. 2003). Glucocorticoids increase the production of
cystatin C (Bjarnadottir et al. 1995, Risch et al. 2001), and glucocorticoid medication
should therefore be taken into account when interpreting serum cystatin levels in renal
transplant patients (Risch et al. 2001).
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2.2. Urinary excretion of low molecular weight proteins as the marker of AR
Low molecular weight (LMW) proteins are filtered via the glomerulus, and reabsorbed in
proximal tubular epithelial cells (Hall et al. 1982, Christensen et al. 1998). A normal
kidney is able to reabsorb 99.9% of the filtered proteins. Megalin on the brush border
surface of the proximal tubular cells mediates the uptake of many small molecular weight
proteins such as α1- and β2-microglobulins and retinol binding protein (Leheste et al.
1999, Christensen 2002). Any disturbance in the function of megalin will result in de-
creased reabsorption and consequently in increased urinary excretion of these proteins.
After renal transplantation, defects in the proximal renal tubules are the earliest and a
constant manifestation of acute graft rejection. Urinary excretions of LMW-proteins usu-
ally increase long before the elevation of other markers of AR, such as a rise of serum
creatinine or general proteinuria (Harrison et al. 1972, Vincent et al. 1979, Beetham and
Cattel 1993). By using SDS-polyacrylamide electrophoresis, Boesken et al. (1974) dem-
onstrated  LMW-proteinuria in 86% of patients with AR, but in none of the patients with
uncomplicated posttransplantation course. High concentrations of urinary β2M have been
reported during or even several days before clinical signs of  acute rejection (Hemming-
sen et al. 1976, Vincent et al. 1979, Bäckman et al. 1986, Prischl et al. 1989, Nishi et al.
1992), whereas a continuous decline of urinary β2M was found in the recipients with
uncomplicated posttransplant outcome (Prischl et al. 1989). Increased urinary excretion
of β2M is not specific for AR but increases also in many other situations such as upper
urinary track infections (Schardijn et al. 1979), tubular necrosis, cyclosporin nephrotoxicity
(Bäckman et al. 1986, Prischl et al. 1989, Nishi et al. 1992, Steinhoff and Sack 1993), and
even with therapeutic CsA levels (Prischl et al. 1989). In addition, significantly elevated
urinary excretion of β2M has been reported in transplant recipients with CMV  infection
(Bäckman et al. 1986, Grundy et al. 1988, Nishi et al. 1992, Steinhoff and Sack 1993). In
these patients the increased urinary concentration of β2M may originate from CMV-
particles which are coated with β2M and excreted in the urine (McKeating et al. 1987,
Grundy et al. 1988). Grundy et al. (1988) recommended that the determination of urinary
β2M in CMV-infected patients must not be carried out before the elimination of CMV-
particles. The instability of β2M in acid urines also limits its use (Davey and Gosling
1982, Donaldson et al. 1989).
Measurement of urinary α1M has many advantages compared to that of β2M. α1M is
stable in urine (Donaldson et al. 1989, Payn et al. 2002) and unlike β2M, its urinary
concentration is not affected by serum paraproteins or by CMV-infection (Bäckman et al.
1986, Grundy et al. 1988, Nishi et al. 1992, Steinhoff and Sack 1993). The excretion of
α1M in the morning urine sample correlates strongly with the daily excretion (Jung et al.
1991). This enables use of a morning urine sample, instead of 24 hr urine, for the determi-
nation of α1M. However, studies of its use in renal transplant recipients are scanty. High-
ly elevated urinary excretion of α1M has been regarded characteristic for CsA nephrotox-
icity (Lapin et al. 1986, Steinhoff and Sack 1993).
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2.3. Markers of renal injury
Several studies have demonstrated that the cells of the proximal tubuli are extremely
sensitive to the immunological and toxic processes, and that the release of enzymes or
proteins such as ala- (leu-gly)-aminopeptidase, χ-glutamyl-transpeptidase, brush border
glycoprotein SGP-240, adenosine deaminase binding protein (ADBP), N-acetyl-β-D-glu-
cosaminidase (NAG), glutathione-S-transferase (GST), and various proximal and dis-
tal tubular derived antigens can be used as an early noninvasive indicator of proximal
tubular cell damage due to graft rejection (Thompson et al. 1977, Whiting et al. 1980,
Thompson et al. 1985, Kotanko et al. 1986, Tolkoff-Rubin et al.1986, Scherberich 1990).
The increased urinary excretion of these markers often precede clinical signs of AR by
several days. Also other events, such as septic episodes, renal artery stenosis or drug
nephrotoxicity may be responsible for tubular damage and increase the urinary excretion
of tubular antigens. Even though the tests are not specific for AR, they provide informa-
tion on location and extent of acute primary tubular damage.
Falkenberg et al. (1986) used sandwich EIA and monoclonal antibodies against various
kidney-derived antigens and showed that increased urinary excretion of many antigens
preceded the clinically recognized rejection by several days and provided information on
location and extent of acute primary tubular damage.  Increased urinary excretion of many
distal-tubular antigens (UA2, UA3, UA9), and the proximal tubular antigens (UA4, UA5,
UA8) were found in patients with AR but also in those with drug nephrotoxicity, whereas
increased urinary excretion of tubular basement membrane antigens UA6 and UA13 were
found only during AR episodes. The increased urinary excretion of UA13 distinquished
rejection from nephrotoxic effects (Falkenberg et al. 1986). Also Limberg et al. (1994)
showed that the increased urinary excretion of UA13 was specific to AR and clearly
preceded the clinically diagnosed rejection. These findings are consistent with the find-
ing of Nadasdy et al. (1988) who demonstrated the injury of ultrastructure of the tubular
epithelium as the first sign of AR.
The increased urinary excretion of ADBP located on the brush border of the proximal
tubular epithelial cells has been found already 7 days prior the clinical diagnosis of AR
(Thompson et al. 1985, Tolkoff-Rubin et al. 1986). Kotanko et al. (1986) reported that by
assaying the following four urinary enzymes: fructose-1,6-bisphosphatase (FBP),
glutathione-S-transferase (GST), N-acetyl-β-D-glucosaminidase (NAG), and pyruvate
kinase (PK)  graft rejection could be diagnosed in patients treated with azathioprine and
prednisolone with 100% sensitivity, 85% specificity and with 45% positive predictive
value. The sensitivity, specificity, and positive predictive value of these tests in CsA treat-
ed patients were 40%, 99%, and 33%, respectively. Irrespective of therapy, 81% of AR
episodes were diagnosed correctly by GST, 71% by FBP, and 57% by NAG. By using a
combination of serum creatinine and urinary excretions of neopterin and FBP, AR was
diagnosed with 100% sensitivity, 89% specificity, and with 15% and 100% predictive
value of positive  and negative tests, respectively (Heiss et al. 1988).
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Glutathione-S-transferase alpha (α-GST) is located in proximal tubular cells, and the pi-
form (π-GST) in the distal tubulus, thin loops of Henle and in the collecting ducts (Bäck-
man et al.1988,1989, Harrison et al. 1989, Campbell et al. 1991, Sundberg et al. 1994,
Daeman et al. 1997, Branten et al. 2000). The determination of the urinary concentrations
of  both α- and π-GSTs have been widely used to identify AR, and to distinguish AR
episodes from infections and from CsA nephrotoxicity. AR results in increased urinary
concentration of π-GST, whereas patients with CsA toxicity had a urinary concentration
of π-GST equal to that of healthy subjects or of  patients with stable renal function (Bäck-
man et al. 1989, Sundberg et al. 1994). On the other hand, the increased urinary levels of
α-GST are characteristic for CsA toxicity, whereas patients with AR had urinary levels of
α-GST only slightly higher than the levels of healthy persons or patients with stable renal
function (Bäckman et al. 1989, Sundberg et al. 1994, Stegeman et al. 1996). Determina-
tion of α-GST in the graft perfusate has been shown to be valuable also in the monitoring
of the viability on non-heart-beating donor kidneys (Daeman et al. 1997, Kievit et al.
1997). Infections did not increase the urinary levels of neither of these enzymes (Bäck-
man et al. 1988, 1989, Sundberg et al. 1994).
2.4. Markers of immunological activation
Activated T-lymphocytes mediate allograft rejection. Their demonstration in transplant
biopsies or in fine-needle aspirates or the determination of their products has been used to
facilitate the clinical monitoring of the patients.
The activation and proliferation of graft infiltrating lymphocytes results in  increased
expression of IL-2 (Simpson et al. 1989, Cho et al. 1998). Before any clinical signs of
rejection were present, intragraft expression of IL-2 mRNA was able to discriminate pa-
tients with AR (Dallman et al. 1992, Kirk et al. 1995). IL-2, in turn, stimulates T-cell
proliferation and induces the expression of its own receptor IL-2R on the surface of acti-
vated T-lymphocytes. The extracellular, soluble part of this receptor (sIL-2R) is shed
from the molecule and excreted into serum and urine.
Initially after transplantation no IL-2R exists in tubular cells, but it appears simultaneous-
ly with the activated lymphocytes and blast cells. The IL-2R positive cells disappear from
the grafts with reversible rejection, but persist in the irreversible rejection (von Wille-
brand et al. 1992). The detection of cells expressing IL-2R in fine-needle aspiration sam-
ples offers a valuable test to discriminate patients with AR from those with CsA toxicity
(Almirall et al. 1992, Gonzales-Posada et al. 1992, von Willebrand et al. 1992). Also the
increases of serum sIL-2R are associated with AR (Colvin et al. 1989, Schroeder et al.
1992, Montagnino et al. 1995, Cho et al. 1998), whereas some authors did not find serum
sIL-2R to be significantly different in patients with and without AR (Bock et al. 1994,
Pickeral et al.1997). In addition to AR, also other causes of T-lymphocyte activation such
as bacterial and viral infections and antilymphocyte therapy result in increased concentra-
tions of IL-2R, whereas CsA nephrotoxicity does not affect serum IL-2R levels (Colvin et
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al. 1989).The regular monitoring of IL-2R serum levels may offer an useful means to
differentiate AR episodes from CsA toxicity, and to follow the effect of antiviral therapy.
Except for some patients with CMV infection, increased urinary levels of IL-2 and IL-2R
have been found only in renal transplant recipients with AR (Simpson et al.1989, Bock et
al.1994, Casiraghi et al.1997).
2.5. Adhesion molecules as markers of AR
Adhesion molecules play an important role in cellular recognition and antigen presenta-
tion. A prominent expression of adhesion molecules has been noted in renal tissue and in
the infiltrating cells in rejecting kidneys (Bishop and Hall 1989, Hill et al. 1995, Loong et
al. 1996, von Willebrand et al. 1996). De novo synthesis of intercellular adhesion mole-
cule-1(ICAM-1) was associated with the severity of rejection (Faull and Russ 1989).
ICAM-1 positivity in the cells of urine sediments has been regarded as the most specific
marker of AR (Roberti et al. 1997).
Soluble forms of adhesion molecules (sICAM-1, sVCAM-1, soluble E-selectin) are shed
from the molecules and secreted into the surrounding fluid (Rothlein et al. 1991, Seth et
al. 1991). Increased serum levels have been shown in patients with acute renal rejection
(Stockenhuber et al. 1993, Bricio et al. 1996) and with inflammation (Seth et al. 1991).
Markedly elevated serum sICAM-1 and sVCAM-1 levels were found during CMV infec-
tion both in renal transplant recipients and in immunocompetent patients. The concentra-
tion of sVCAM-1 associated with serum creatinine in renal transplanted patients (Eriks-
son et al. 2001).
High urinary levels of sICAM-1 have been reported in patients with AR especially in
those with steroid resistant AR (Bechtel et al. 1994).
2.6. Markers of inflammation
Interleukin-1 (IL-1) is produced by activated monocytes/macrophages. During AR epi-
sodes, highly increased amounts of IL-1 have been found in renal tissue and in the glomer-
ular mesangium (Loong et al. 1996), and increased concentrations of IL-1 have been
measured also in plasma (Maury and Teppo 1988). IL-1 is implicated in many ways in AR
of renal grafts. Among other things, it induces the release of IL-6 from various cells
(Boswell et al. 1994) and the synthesis of serum amyloid A protein (SAA) in the liver
(McAdam et al. 1982, Sipe et al. 1982). IL-1 has an endogenous inhibitor IL-1ra that
binds to IL-1 cell receptors and completely blocks the effects of IL-1 at the cell surface,
among other things the IL-1-induced synthesis of SAA (Bevan and Raynes 1991). The
low SAA concentrations found in nonrejecting patients may thus be due to high IL-1ra
concentrations. The finding that transgenic mice overexpressing IL-1ra had significantly
lower levels of SAA than their wild-type littermates supports this assumption (Palmer et
al. 2003).
20
Different stimuli such as surgical trauma, AR, infection, inflammation, and antilymphocyte
therapy induce SAA production. AR causes markedly higher serum SAA concentrations
than infections or other complications (Maury and Teppo 1984, Casl et al. 1995).Triple
immunosuppression suppresses the response of CRP to transplantation surgery and to AR
but affects much less that of SAA (Maury and Teppo 1984, Casl et al. 1995, Hartmann et
al. 1997). During AR, more than 98% of patients receiving both CsA and methylpred-
nisolone had SAA levels over 100 mg/l (Maury et al. 1983). Patients with steroid-sensi-
tive AR have much lower values of SAA than those with steroid-resistant rejection. The
determination of SAA has also proved to be of great value  in the detection of patients
with subclinical rejection (concentration of SAA < 100 mg/l), and in monitoring the re-
sponse to antirejection therapy (Maury et al. 1983, Casl et al. 1995, Hartmann et al. 1997).
During AR, but not in patients with  stable graft function or in healthy controls, heavy
intragraft IL-6 mRNA expression takes place in a variety of renal cells including glomer-
ular, tubular epithelial, smooth muscle, and interstitial mononuclear cells (Vanderbroecke
et al.1991,Yoshimura et al.1991, Raasveld et al.1993, DiPaolo et al.1997). The urinary
excretion of IL-6 was shown to correlate with its intrarenal expression (DiPaolo et al.
1997), and highly increased urinary levels of IL-6 have been detected during or a few
days before AR episodes (Van Oers et al. 1988, Casiraghi et al. 1997, DiPaolo et al. 1997,
Waiser et al. 1997, Kaden and Priesterjahn 2000). A sudden increase of urinary IL-6 is
characteristic for AR (Casiraghi et al. 1997) and was detected on an average three days
before clinical signs of rejection (Waiser et al. 1997). Increased urinary excretion of IL-6
was found also in patients with acute tubular necrosis, bacterial and viral infections, and
with antithymocyte globulin and OKT3 treatment (Waiser et al. 1997, Kaden and Priester-
jahn 2000), whereas CsA toxicity resulted in reduced urinary excretion of IL-6 (Yoshimu-
ra et al. 1991). The sequential monitoring of urine concentrations of IL-6 could be used to
distinguish patients with AR from those with CsA toxicity (Yoshimura et al. 1991).
IL-6 induces the synthesis of CRP in hepatocytes. Increased  serum concentrations of
CRP thus reflect the activation of IL-6 (Bataille and Klein 1992). Before the use of CsA,
serum concentration of CRP served as an useful indicator of AR (White et al. 1981, Freed
et al. 1984, Rowe et al. 1987, Harris et al. 1996). In patients treated with cyclosporine the
responses of CRP to transplantation surgery and to AR are blunted and frequently com-
pletely absent (Maury and Teppo 1984, Cohen et al. 1988, Casl et al. 1995, Hartmann et
al. 1997, Oyen et al. 2001), whereas the response of CRP to current infections is not
(Hartmann et al. 1997). The most astonishing feature is that, in spite of similar triple
immunosuppression, the response of CRP to transplant surgery and to AR  varies enor-
mously from patient to patient. The peak response of CRP to surgical trauma has been
shown to vary from 5 to 88 mg/l, and to AR from 0.4 to 222 mg/l (Casl et al. 1995, Harris
et al. 1996, Hartmann et al. 1997, Oyen et al. 2001). The rise of CRP concentration in a
wide variety of inflammatory conditions and its modest or absent response to AR greatly
restricts its use in the detection of AR episodes. Serial measurements of serum CRP are,
however, of great value in the early detection of infections and postoperative complica-
tions (Oyen et al. 2001, Reek et al. 2001).
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2.8. New tools to detect AR
Deposition of C4d along peritubular capillaries has been associated with the antibody-
dependent rejection, accelerated graft loss (Feucht et al. 1993, Regele et al. 2001), and
development of CAD (Mauiyyedi et al. 2001, Magil and Tinckam 2003). Patients with
steroid-resistant AR excreted C4d in urine 10-fold more, and patients with steroid-sensi-
tive AR and with CAD 5-fold more than the healthy subjects, whereas in patients with
stable graft function the urinary excretion of C4d was  equal to that of healthy subjects
(Lederer et al. 2003). The determination of C4d in urine may thus offer an easy, non-
invasive tool for assessing the severity and type of allograft rejection and for clinical
monitoring of renal transplant patients.
The recent development of proteomic technology that combines mass spectrometry with
affinity chromatography and gene technology allows the rapid and reproducbile  screen-
ing of protein expression profiles or ”phenomic fingerprints” in normal and pathologic
urines or sera (Amlot 2003, Thongboonkerd 2004). By using this technique, Clarke et al.
(2003) and Schaub et al. (2004) found two different urine protein patterns specific for
acute rejection. Unfortunately, the authors failed to identify these biomarker candidates.
On the other hand, by using similar technique Hampel et al. (2001) identified β2-mi-
croglobulin, retinol binding protein and carbonic anhydrase as the urinary biomarker can-
didates for AR, and Tomosugi et al. (2003) identified amyloid A protein and β2-microglob-
ulin as the serum biomarkers for AR.
In a systemic study of gene-expression pattern in biopsies from normal and dysfunction-
ing renal allografts, Sarwal et al. (2003) found distinguishable gene expression profiles
among samples from patients with AR, nephrotoxicity, infection, and CAD. Moreover,
they found that even though by light microscopy CD8- and CD4-positive T-lymphocytes
were seen in all samples from acutely rejecting grafts, the T-cell-inducible mRNA tran-
scripts differed markedly among the samples. This finding indicated great heterogeneity
between acute rejections at the molecular level. By using immunohistochemical stainings
to further define these various subtypes, they found striking associations between CD 20-
positive T-cells and glucocorticoid resistance and between these cells and graft loss (Sar-
wall et al. 2003). This finding is especially interesting, because it not only offers a means
to identify steroid-resistant rejection but also provides the hypothetic possibility for its
management by using monoclonal antibodies against CD 20 (Marsden 2003, Sarwall et
al. 2003).
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Part 2. Chronic allograft dysfunction
1. General aspects of chronic allograft dysfunction
1.1. Definition and clinical picture
The terms chronic allograft dysfunction (CAD) and chronic allograft nephropathy (CAN)
have been introduced to describe the functional and structural changes in the graft. The
term CAD describes the syndrome that begins three months or more after transplantation,
and is clinically characterized by a relative slow but regular (Modena et al. 1991) or
variable progressive (Kasiske et al. 1991a)  loss of renal function. It often starts together
with increasing proteinuria (Harlan et al. 1967, Barnas et al. 1997, Paul 1999, Silkensen
2000, Roodnat et al. 2001) and aggravation or de novo appearance of hypertension (Pon-
ticelli et al. 1993, Vianello et al. 1993, Monaco et al. 1999, Paul 1999), but usually with-
out specific symptoms (Hostetter 1994, Burke et al. 1995, Matas 1998, Ponticelli 2000).
The onset and progression of CAD may vary among patients (Kasiske et al. 1991a) but
the present definition includes that the deterioration of renal function is associated with
characteristic histologic lesions that cannot be attributed to recurrence of original disease
or to other causes of graft dysfunction (Kasiske et al. 1991 b, Brenner and Milford 1993,
Paul et al. 1993, Burke et al. 1995, Matas 1998, Kreis and Ponticelli 2001). The term
chronic rejection is now usually reserved for immunologically mediated injury (Halloran
2002).There is still no doubt that an alloimmune response lies behind most, if not all, of
the cases of chronic allograft nephropathy. The nature of this immune response is be-
lieved to be different from that of acute rejection (Womer et al. 2000).
Proteinuria  greater than 0.5 g/24 h is present in 20 to 40% of patients (Paul 1999, Rood-
nat et al. 2001), and greater than 1 g/24 h in 6% of patients (Paul and Sijpkens 2001).
About 90% of patients have some degree of hypertension (Modena et al. 1991). The
clinical manifestations are not specific, and the diagnosis of CAD is made on the basis of
histological findings by excluding other causes of graft dysfunction (Hostetter 1994, 2003).
1.2. Incidence of CAD
Chronic transplant dysfunction is recognized as the primary cause of allograft loss after
the first posttransplantation year (Azuma and Tilney 1994, Kasiske 1997). Even though
the long-term renal graft survival has improved markedly in the recent decade (Hariharan
et al. 2000, Womer et al. 2000), still 4% of renal transplants are annually lost after the first
posttransplant year due to CAD (Ceska 1997, Paul 1999, Hariharan et al. 2000, Ponticelli
et al. 2002, Gourishankar et al. 2003, Salmela and Kyllönen 2003). CAD is the single
most prevalent cause of initiation of dialysis and retransplantation. The second major
cause of late renal allograft loss is patient death  caused primarily by cardiovascular dis-
ease (Hostetter 1994, Paul 1995, Jindal and Hariharan 1999, Kreis and Ponticelli 2001,
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Gourishankar et al. 2003). In Finland, half of transplant recipients deaths is caused by
cardio- or cerebrovascular diseases (Salmela and Kyllönen 2003).
1.3. Histological picture
Chronic allograft nephropathy (CAN) is histologically characterized  by patchy fibrosis
in the interstitium, tubular atrophy, characteristic glomerular lesions and by vascular wall
thickening involving the intima (Solez et al. 1993, Racusen et al. 1999). The changes are
not necessarily present simultaneously or in the same degree. The perivascular inflamma-
tion with infiltration of T-cells and macrophages into the interstitium is also frequently
seen (Demetris et al. 1989). These changes are characteristic but not specific for CAN.
Especially, CsA nephrotoxicity is often histologically difficult to distinquish from CAN
(Jindal and Hariharan 1999). Highly indicative of CAN are fibrous intimal thickening
and transplant glomerulopathy (Solez et al. 1998, Monaco et al.1999). The latter occurs
on an average in 15% of patients with CAN (Monaco et al.1999).The Banff 1997 classi-
fication uses the term CAN to describe the changes seen in the interstitium, tubuli, glomer-
uli, and vessels (Racusen et al. 1999). The characteristic changes of chronic vascular
rejection are included but not demanded for the diagnosis of CAN, since they are regard-
ed less characteristic for chronic graft damage than interstitial fibrosis or tubular atrophy
(Freese et al. 2001). The changes in the interstitium and in the tubuli are the basis for
grading the severity of CAN (Racusen et al. 1999).
The most severe form of CAN, chronic vascular rejection (CVR) resembles the early
atherosclerotic lesion and is also called transplant atherosclerosis (Foegh 1990). The term
CVR is used for changes that include vascular intimal proliferation and hyperplasia as its
major characteristic together with either transplant glomerulopathy/glomerulosclerosis,
interstitial fibrosis or tubular atrophy (Solez et al. 1993). Clinically CVR is characterized
by impaired renal function and proteinuria (Dimeny et al. 1995 a). Acute rejection epi-
sodes, suboptimal immunosuppression (Almond et al. 1993), and pretransplant hyperc-
holesterolemia (Dimeny et al. 1993, 1995 b) were found to be the major risk factors for
the development of CVR. CVR is responsible for the majority of graft losses after the first
posttransplant year.
The term chronic rejection (CR) has been proposed for those grafts which have alloanti-
body-mediated graft injury (Halloran and Melk 2001, Halloran 2002), and which show
accumulated neutrophils together with uniform staining of complement split product C4d
in the peritubular capillaries (Halloran and Melk 2001, Regele et al. 2001, 2002, Roy-
Chaudhury et al. 2002, Watschinger and Pascual 2002). The histological markers of chronic
rejection are transplant capillaropathy and glomerulopathy. The circumferially multilay-
ered peritubular capillaries are also correlated to the presence of CR. In most studies
where only light microscopy has been used, CR has consisted 20 to 30% of CAN but the
true incidence may be as high as 70% (Ivanyi 2003).
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1.4. Immunological risk factors
Tissue injury caused by immunological or non-immunological factors initiates a cascade
of molecular and cellular events which are believed to lead gradually to the deterioration
of graft function (Fellström 1995, Paul et al. 1995, Tullius and Tilney 1995, Häyry et
al.1999, Monaco et al. 1999, Paul et al. 1999). The role of immunological factors in the
pathogenesis of CAD is supported by the facts that all recipients with an allograft should
take life-long maintenance immunosuppressive medication, and that CAD rarely devel-
ops in recipients without previous AR (Almond et al. 1993, Matas 1998, Humar et al.
2000, Paul 2000). Immunological factors that may cause tissue injury include AR epi-
sodes, HLA incompatibility between donor and recipient, production of antibodies to
donor cells, and inadequate immunosuppression (Abe et al. 1997, Paul 2001).
A number of studies have shown AR episodes to be the major risk factor for CAD (Al-
mond et al. 1993, Meier-Kriesche et al. 2000). The number of AR episodes (Cecka 1991,
Gulanikar et al. 1992, Basadonna et al. 1993, Kiley et al. 1993, Lindholm et al. 1993, Tesi
et al. 1993, Matas et al. 1994, Cosio et al. 1997), their late occurrence (Basadonna et al.
1993, Lindholm et al. 1993, von Saase et al. 1995, Leggat et al. 1997, Matas 1998, Khauli
et al. 2001), especially the first acute rejection that occurs after the first posttransplant
year (Kiley et al. 1993, Massy et al. 1996), and repeated, severe, prolonged or persistent
AR episodes markedly increase the risk for CAD (van Saase et al. 1995, Shimizu et al.
2002). In the series of 1799 renal transplant recipients, graft survival at 12 years post-
transplantation was 90%  in patients who had had no AR, 70% in those who had had one
AR episode, and 40% in whose patients who had experienced more than one acute rejec-
tion episode (Shishido et al. 2003).
HLA incompatibility between donor and recipients has been suggested to increase the
risk for CAD (Feucht and Opelz 1996, Massy et al. 1996, Morris et al. 1999, Sijpkens et
al. 1999, Womer et al. 2000). Suciu-Foca et al. (1991) demonstrated that long-term sur-
vival of renal allografts was significantly lower in patients who had anti-HLA-antibodies
after transplantation than in patients who had no antibodies. They suggested that CAD is
mediated by antibodies against mismatched HLA antigens in the graft. In agreement with
this assumption, several groups have shown alloantibodies to donor HLA class I and II
antigens to associate with the development of CAD (Jeannet et al. 1970, Abe et al. 1997,
McKenna et al. 2000, Fernandes-Fresnedo et al. 2003). The presence of these circulating
antibodies often precede the clinical manifestations of CAD (Mauiyyedi et al. 2001).
Although there is general consensus that tissue typing and good HLA matching is predic-
tive of improved short-term renal outcome (Cecka 1997), it is not clear whether increased
number of mismatches anticipates worse long-term outcome. No significant difference
was noticed between patients with HLA-AB mismatches < 2 and those with HLA-AB
mismatches ≥ 2 in the 7-year allograft survival rates, or between patients with matched or
mismatched HLA antigens in 10-year graft survival rates (Kerman et al. 1996).
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Tesi et al. (1993) reported that the patients with high number of HLA mismatches had less
acute rejections than those with low number and that neither the number of HLA mis-
matches nor the current or maximum amount of antibodies to HLA antigens predicted
graft survival. Also Sijpkens et al. (1999) failed to demonstrate any relationship between
HLA mismatches and poor long-term outcomes. On the other hand, Poggio et al. (2004)
showed that patients with CAN had antibodies to donor HLA molecules more frequently
than those without CAN.
There is clinical evidence that suboptimal blood levels of cyclosporine are associated with
an increased incidence of AR episodes, and that it is a risk factor for CAD as well (Almond
et al. 1993, Isoniemi et al. 1994 a, Kahan et al. 1996, Barnas et al. 1997,  Nickerson et al.
1998). High intraindividual variability of CsA blood concentrations has also been regarded
as a risk for CAD (Inoue et al. 1994, Savoldi et al. 1997, Waiser et al. 2002).
1.5. Non-immunological risk factors
Factors such as early injury from ischemia and reperfusion, infections, posttransplant
hypertension, hyperlipidemia, and proteinuria have been reported as risk factors for CAD.
Donor kidneys undergo a series of damaging ischemic events during graft retrieval, stor-
age and transplantation. Several studies have demonstrated that ischemia and reperfusion
injury result in augmented expression of various adhesion molecules, cytokines and growth
factors (Wanders et al. 1995, Waltenberger et al. 1996, Azuma et al. 1997), and that
prolonged injuries or impaired repair from injury are high risks for CAD (Yokoyamata et
al. 1994, Fellström 1995, Land and Messner 1996, Shoskes and Halloran 1996, Halloran
et al. 1997, Waaga et al. 1997, Paul 2000).
Some studies have shown an association between CMV infections and the development
of CAD (Almond et al. 1993, Hirata et al. 1996, Humar et al. 1999), while others have
failed to demonstrate this association (Dickenmann et al. 2001). The findings that CMV
infection is common in renal allografts (Liapis et al. 2003) and that patients with CMV
infections are more prone for AR episodes suggest the role of CMV infections in expos-
ing the graft to AR and also to CAD (Pouteil-Noble et al. 1993, Reinke et al. 1994,
Sageda et al. 2002).
Donor-related factors such as graft size or female gender (Brenner et al. 1992, Almond et
al. 1993, Abdi et al. 1998), poor quality of graft (Vianello et al. 1993, Burke et al. 1995,
Sund et al. 1999, Barbari et al. 2001) and advanced age (Brenner and Milford 1993,
Gjertson 1996, Matas 1998,  Kerr et al. 1999, De Fijter et al. 2001) have been shown to
increase the risk for CAD.
Several recipient-related factors such as hypertension (Brazy et al. 1992, Barnas et al.
1997, Midvedt and Hartmann 2002), hyperlipidemia (Dimeny et al. 1995 b, Dimeny and
Fellström 1997, Roodnat et al. 2000), posttransplant diabetes (Woo et al. 1999), insulin
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resistance (de Vries et al. 2003), high or low body mass (Meier-Kriesche et al. 2002),
male gender (Meier-Kriesche et al. 2001), smoking (Kasiske and Klinger 2000), and old
age (Carter et al. 2000, Liu et al. 2001) have been shown to associate with the develop-
ment of CAD.
1.6.  The role of TGF-β in chronic allograft dysfunction
Early structural injury is thought to initiate a cascade of growth factor and cytokine pro-
duction that gradually leads to graft fibrosis (Border and Ruoslahti 1992, Lemström et al.
1995, Paul 2000, Baboolal et al. 2002). TGF-β1 initiates and terminates tissue repair and
thus has a crucial role in the development of CAD (Border et al. 1990, Border and Ruo-
slahti 1992, Border and Noble 1994, Yamamoto et al. 1994,  Brenchley et al. 1998, Hutch-
inson 1999, Jain et al. 2000 b). It stimulates fibroblasts to produce collagen, fibronectin,
and other extracellular matrix proteins (Ignotz and Massaque 1986, Border and Noble
1994), and inhibits their degradation (Furness 1996). TGF-β1 also takes part in tubular
epithelial cell differentiation into myofibroblasts that may be important in the developing
of interstitial fibrosis and of CAD (Fan et al. 1999, 2001). Interstitial fibrosis is caused by
increased deposition of extracellular matrix components such as fibronectin and types I
and III collagen in the kidney. The amount of both interstitial fibrosis (Nicholson et al.
1996) and of type III collagen (Nicholson et al. 1999 a) in protocol biopsy have been
shown to predict long-term graft function. Type III collagen is synthesized as a procolla-
gen with amino-terminal arms at both ends of the molecule. During the synthesis and
deposition of collagen, amino-terminal propeptide (PIIINP) is degraded from the mole-
cule and excreted into the surroundings. Increased circulating PIIINP has been shown to
reflect ongoing fibrotic processes in many organs (Low et al. 1983, Frei et al. 1984)  and
increased urinary PIIINP level has been suggested to be a useful predictor of progressive
renal fibrosis (Eddy 1996, Soylemezogly et al. 1997).
There is some evidence that genotypically high TGF-β producers are more prone for
losing their grafts (Hutchinson 1999) and that continuing or repetitive tissue injury caus-
es a defect in the regulation of TGF-β1 and  persistently increased production of TGF-β1
then gradually leads to tubulointerstitial fibrosis and glomerulosclerosis (Paul 2000). In a
rat model of renal transplantation, chronic immunological injuries were associated with
persistently increased expression of TGF-β1 and marked fibrosis (Diamond et al. 1992,
Paul et al. 1996, Shihab et al. 1996).
Highly increased TGF-β staining has been demonstrated in the tubulointerstitium of grafts
with CAN (Gaciong et al. 1995, Shihab et al. 1995, Cuhaci et al. 1999). Intragraft expres-
sion of TGF-β1 mRNA was associated with the use of CsA (Pankewycz et al. 1996,
Baboolal et al. 2002), the degree of interstitial fibrosis (Sharma et al. 1996, Pankewycz
2000, Baboolal et al. 2002), increased rate of decline in renal function (Cuhaci et al.
1999, Hutchinson 1999), and intragraft deposition of collagen III (Nicholson et al. 1999
a, b). Baboolal et al. (2002) hypothesized that longitudinal measurement of renal allograft
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expression of TGF-β, thrombospondin and fibronectin would provide a sensitive indica-
tor of the response of graft to injury and the onset of CAD.
Increased intragraft expression of TGF-β1 could be thought to result in its increased plas-
ma and urine concentrations. There are only few papers supporting this. Noh et al. (1993)
showed a correlation between urinary concentration of TGF-β1 and the indices of inter-
stitial fibrosis in rabbits. In human renal transplant recipients, plasma – but not urinary –
levels were higher than in the healthy subjects, whereas no significant difference was
found in plasma concentrations of TGF-β1 in patients with stable graft function and in
those developing CAD (Coupes et al. 1994). On the other hand, Gaciong et al. (1995)
showed higher urinary excretion of TGF-β1 in patients who developed CAD than in those
with stable graft function.
TGF-β1 is secreted as an inactive complex associated with latency associated protein
(LAP) (Brenchley et al. 1998). Alterations of pH, several proteolytic enzymes, and throm-
bospondin – the activator of latent TGF-β -  can release biologically active TGF-β1 (Jain
et al. 2000 b). Activated TGF-β1 can be inhibited and/or bound by local factors (Yamaguchi
et al. 1990, Border et al. 1992). The excretion of TGF-β1 is suggested to reflect the
balance between the release and the binding of TGF-β1 (Jain et al. 2000 b). Most antibod-
ies used in immunological assays detect both active and inactive TGF-β1.
2. Surrogate markers of chronic allograft dysfunction
2.1. Histological findings of protocol biopsies as a surrogate marker
of graft survival
Several studies have confirmed that careful evaluation of protocol biopsies taken relative-
ly early after transplantation before any signs of functional deterioration can provide sig-
nificant information about graft prognosis. Kuypers et al. (1999) and Mueller et al. (2000)
showed that the quality of the donor organ and the occurrence of acute vascular rejection
increased the risk for CAD, whereas others reported that the histological evidence of the
occurrence of any type of, even asymptomatic, AR episodes associates with histological
findings of CAN at two years after transplantation (Rush et al. 1995, Legendre et al.
1998, Solez et al. 1998).
The use of Banff criteria (Solez et al. 1993, Racusen et al. 1999) for chronic allograft
nephropathy changes has standardized and greatly facilitated the interpretation of renal
biopsy findings of CAN.
The degree of histological changes, particularly the extent of interstitial fibrosis and of
tubular atrophy,  in protocol biopsies taken at three months (Seron et al. 1997, Kuypers et
al. 1999) or between six  months to two years have been shown to correlate with the graft
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outcome during the two to eight years follow-up (Kasiske et al. 1991 b, Isoniemi et al. 1992
and 1994 a,b, Nickerson et al. 1998, Rush et al. 1998 b, Solez et al. 1998, Freese et al. 2001,
Furness 2001). The increase of interstitial fibrosis and tubular atrophy between the biopsies
taken at implantation and at one year after transplantation was also associated with subse-
quent deterioration of graft function (Sund et al. 1999, Seron et al. 2000, 2002).
2.2. Graft function as the predictor of long-term outcome
Early detection of graft dysfunction is crucial in the follow-up of renal transplant recipi-
ents. Serum creatinine and creatinine clearance have been proposed as indicators of graft
outcome (Hariharan et al. 2002, Kasiske et al. 2002, Pokorna et al. 2002). Increased
serum creatinine at three month (Woo et al. 1999), at six month (Matas 1998, Monaco et
al. 1999, Prommool et al. 2000, Hariharan et al. 2002, First 2003) or at one year (Almond
et al. 1993, Matas 1998, Hariharan et al. 2002, Ponticelli et al. 2002) was regarded as
strong surrogate marker for CAD, whereas normal serum creatinine indicated good long-
term prognosis of graft. On the other hand, normal or slightly elevated serum creatinine
values at one year did not exclude the presence of histopathological changes. Yilmaz et
al. (2003) showed that 40% of patients who had serum creatinine less than 135 mmol/l at
one year had chronic allograft damage index (CADI) over 2.0. In a retrospective study of
more than 100.000 renal transplant recipients from year 1988 to 1998, 6 month serum cre-
atinine levels under 135 mmol/l, from 230 to 265 mmol/l, and over 265 mmol/l gave 5-year
graft survival rates 80%, 55%, and less than 40%, respectively (First 2003). Elevated serum
creatinine at one year seems to be the most accurate predictor of 3- and 5-year graft survival,
and each incremental increase of serum creatinine from six month to one year appears to be
associated with progressive decline in graft half-life (Hariharan et al. 2002, First 2003).
Yilmaz et al. (1995) and Setterberg et al. (2000) regarded the area under the serum creati-
nine time curve (AUC/time) calculated from 3 weeks to 3 months after transplantation as
the best predictor of CAD. Impaired GFR at six or 12 months after transplantation indicated
the risk for CAD, and the slope of GFR between six and 12 months correlated with the rate
of progression of CAD (Kasiske et al. 2002). In a large retrospective study of pediatric renal
transplant recipients, creatinine clearance of less than 50 ml/min determined either one
month or one to three years after transplantation gave 3-year graft survival rate (calculated
from the time of determination) of 65%, whereas creatinine clearance of over 50 ml/min
gave 3-year graft survival of an average 91% (Tejani et al. 2002).
2.3. Hypertension
Systemic hypertension is present in 70-90% of renal transplant recipients (Ponticelli et al.
1993, First et al. 1994, Van der Shaaf et al. 1995). The degree of hypertension has been
reported to associate with the severity of histological (Kasiske et al. 1991 b) and function-
al (Modena et al. 1991) damage of the graft, and to be a powerful predictor of proteinuria
(Calvino et al. 2000), CAD (Bia 1995, Kasiske 1997) and graft loss (Kasiske et al. 1991
a, Modena et al. 1991, Ponticelli et al. 1993, Opelz et al. 1998, Sorof et al. 1999). Both
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diastolic (Brazy et al. 1992) and systolic (Barnas et al. 1997) blood pressures are associ-
ated with more rapid decline in GFR  and, at one year after transplantation, both have
been regarded strongly predictive of allograft survival (Mange et al. 2000).The use of
calcineurin inhibitors increases the risk for hypertension (Sorof et al. 1999).
Arterial hypertension could result in graft dysfunction by causing intraglomerular hy-
pertension and streching which, in turn, stimulate the local production of angiotensin II.
This induces the expression of TGF-β1 that has a role in the progression of interstitial
fibrosis and  in the development of CAD. In addition, TGF-β1 can stimulate the production
of renin and thus initiate a vicious circle. The findings that the blocking of the renin-angi-
otensin system effectively reduced post-transplant hypertension (Midtvedt and Hartmann
2002), slowed the rate of progression of established CAD and improved long-term graft
survival (Zalzman et al. 2004) support the role of hypertension in the development of CAD.
2.4. Proteinuria
Transient proteinuria that persists less than 6 months is generally associated with a fa-
vourable prognosis of the graft (Artz et al. 2003), whereas persistent heavy proteinuria at
6 or more months is  strongly associated with reduced graft function and survival (First et
al. 1984, Vathsala et al. 1990, Peddi et al. 1995, McLaren et al. 2000, Braun et al. 2001,
Roodnat et al. 2001, Reichel et al. 2004). In a rat model, progressive albuminuria was
associated with the development of glomerulosclerosis (Diamond et al. 1992). In 35% of
patients with CAN proven with biopsy, daily urinary excretion of protein exceeded 1g/24
hours, and in 70-80% of patients it exceeded 0.5 g/24 hours (Massy et al. 1996). At six
months after transplantation, proteinuria (0.25- 1.0 g/24 hours) has been reported in 10-
40% of recipients (Massy et al. 1996, Hohage et al. 1997, Paul 1999, Roodnat et al.
2001), and over 1 g/24 hours in 6% of patients (Paul and Sijpkens 2001). Massy et al.
(1996) reported the prevalence of proteinuria to be four times higher in patients who
developed CAD than in those with stable graft function. Hohage et al. (1997) reported 5
year graft survival to be 86% in non-proteinuric patients but only 59% in proteinuric
patients. Also McLaren et al. (2000) who retrospectively followed 862 primary renal
graft recipients over a 10 year period showed that proteinuria at one year after transplan-
tation predicted  graft failure. In over 450 renal transplant recipients, Barnas et al. (1997)
showed a persistent proteinuria exceeding 2 g/24 hours to have a positive predictive value
of 83%, and a proteinuria exceeding 1g/24 hours 71% in identifying the patients whose
graft function will deteriorate more than 25% within 2 years. Rademacher et al.(2003)
reported proteinuria exceeding 1g/24 hours to have 95% specificity, and 70% positive
predictive value in identifying the patients whose GFR will decrease at least by 50%
during the following three or more years.
In general, all studies have concluded that proteinuria is an excellent marker of poor long-
term prognosis. Reichel et al. (2004) regarded proteinuria as the most sensitive marker of
allograft dysfunction, possibly only inferior to histopathological findings of protocol bi-
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opsies. The degree of proteinuria and the composition of urinary proteins seem to have
importance as well. The patients with mild and/or selective albuminuria have much better
prognosis than those with heavy or non-selective proteinuria (Oberbauer et al. 1995, Bar-
nas et al. 1997).
In addition to graft survival, proteinuria is also indicative of patient survival. Roodnat et
al. (2001) showed that patients who had proteinuria at 1 year after transplantation had
1.98 times higher relative risk of death than the non-proteinuric patients. Fernandes-Fresne-
do et al. (2002) confirmed this finding and reported the relative risk for patients death to
be 1.92 times higher in proteinuric patients.The findings that reduction of proteinuria by
ACE inhibitors decreased the rate of decline of renal function and improved graft surviv-
al suggest that proteinuria plays a major causal role in graft loss (Brenner et al. 1993,
Barnas et al. 1996).
Microalbuminuria has been considered as the best predictor of renal risk in diabetic pa-
tients and in patients with hypertension. Microalbuminuria or the transition from nor-
moalbuminuria to microalbuminuria has been proposed as the earliest marker of incipient
proteinuria and of developing CAD also in renal graft recipients (Halimi et al. 2002).
2.5. Hyperlipidemia and the risk for CAD and graft loss
Hypercholesterolemia and hypertriglyceridemia have been shown to associate with an
increased incidence of acute rejection episodes (Dimeny et al. 1993), with histological
CAN-like changes at 6 month biopsies (Dimeny et al. 1995 b), and with renal graft loss
(Dimeny et al. 1995 b and 1997, Hamar et al. 1997). Seron et al. (2000) demonstrated
pretransplant serum cholesterol to be the only independent predictor of vascular lesions
associated with CAN. Posttransplant  hyperlipidemia, and particularly hypercholestero-
lemia, have also been associated with progressive deterioration of renal transplant func-
tion (Isoniemi et al. 1994 a, Dimeny et al. 1995 b, Roodnat et al. 2000). On the other
hand, Wissing et al. (2000) showed that in patients who had had no AR episodes within
the first posttransplantation year, hypercholesterolemia had no impact on graft loss, whereas
patients with a previous AR and hypercholesterolemia over 6.5 mmol/l had a higher inci-
dence of graft loss than patients with serum cholesterol under 6.5 mmol/l. In patients with
AR episode(s) during the first year, hypercholesterolemia was an independent risk factor
for graft loss in male patients (Wissing et al. 2000). Guijarro et al. (1995) studied a series
of 706 consecutive renal transplant recipients and found that increased post-transplant
serum triglycerides, but not total cholesterol, was associated with graft loss due to CAN.
Hyperlipidemias are considered as a risk factor especially for the development of CVR
(Dimeny et al. 1993). In experimental models of CVR, additional dietary cholesterol ac-
celerated the development of atherosclerotic lesions (Fellström et al. 1998).
Fellström (1999) suggested oxidatively modified LDL-cholesterol to be the most impor-
tant hyperlipidemic risk factor for the development of CAN. Oxidized LDL enhances the
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expression of PDGF, MHC class 2 molecules, and adhesion molecules on the endotheli-
um. It also stimulates the synthesis of cytokines and growth factors on glomerular me-
sangial cells that may eventually lead to glomerulosclerosis. One possible explanation of
the harmful role of increased level of LDL-cholesterol is that it increases the amount of
LDL-bound cyclosporine and results in its reduced cellular uptake (Hirano et al. 2001).
The lower CsA bioavailability, in turn, is associated with the development of CAD and
graft loss (Schroeder et al. 1995).
2.6. α-SMA positive myofibroblasts as the predictor of CAD
Myofibroblasts are morphologically intermediate between fibroblasts and smooth muscle
cells. They express α-SMA and have high proliferative capacity (Gabbiani 1992, Hewit-
son et al. 1996). The appearance of myofibroblasts into the tubulointerstitium together
with tubular atrophy and interstitial fibrosis has been regarded as the strongest predictor
of CAD (Nikolic-Paterson et al. 1994, Ko et al. 1997, Pedagogos et al. 1997, Tang et al.
1997, Halloran et al. 1999).The reported simultaneous appearance of myofibroblasts and
both procollagen III mRNA and protein in the renal interstitium suggests synthesis of
collagen III in myofibroblasts (Hewitson et al. 1995, Hewitson and Becker 1996, Peda-
gogos et al. 1997, Tang et al. 1997). In dysfunctioning renal transplants, α-SMA positiv-
ity was associated with increasing interstitial fibrosis and collagen deposition (Boukhalfa
et al. 1996, Abe et al. 2000). In three week biopsies, significantly higher amounts of
myofibroblasts were found in those patients who later developed CAD than in those who
retained stable graft function (Pilmore et al. 2000), and in time-zero biopsies high intersti-
tial expression of α-SMA was found in 86% of the patients who later developed CAD but
only slight α-SMA expression in those with stable graft function. In addition, the amount
of α-SMA positive myofibroblasts was associated strongly with graft outcome (Badid et
al. 2002). On the other hand, Nicholson et al. (1999 a) did not find interstitial α-SMA
staining at 6 month biopsies to be predictive for CAD.
2.7. New tools to predict outcome of renal allograft
Radermacher et al. (2003) measured the renal segmental arterial resistance index (the
percentage reduction of the end-diastolic flow compared with the systolic flow) by Dop-
pler ultrasonography in over 600 patients three or more months after successful renal
transplantation and followed the patients at least for three years. They found that the
patients with a resistance index lower than 80 had a median allograft survival time 23.3
years compared to 2.5 years of the patients who had this index of 80 or higher. The resist-
ance index correlated with age, coronary heart disease, decreased renal function, increased
systolic and pulse pressure and predicted – in addition to graft failure – also patients death
due to cardiovascular disease.This index proved to be significantly better prognostic indica-
tor of renal graft survival than any of the commonly used clinical variables such as late acute
rejection episodes, urinary protein excretion, or low creatinine clearance. So far, this single-
center study has not been confirmed by other groups (Marsden 2003).
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AIMS OF THE STUDY
This study was conducted to find out non-invasive indicators of early posttransplantation
complications and of the development of CAD.
The main objectives were to study:
1. whether the duration of cold ischemia or acute rejection episodes affect the reabsorp-
tion of α1-microglobulin (α1M) and whether the urinary excretion of α1M in patients
developing acute rejection or other complications differs from that of patients with
uncomplicated posttransplantation course. (I)
2. whether urinary excretions of IL-1β or its inhibitor IL-1ra increase during acute rejec-
tion, and whether their excretion can be used to distinguish patients with acute rejec-
tion from those with uncomplicated posttransplantation course. (II)
3. the origin of urinary soluble ICAM-1 and whether the urinary excretion of sICAM-1
can be used to distinguish patients who develop acute rejection from those with stable
graft function. (III)
4. whether urinary excretion of PIIINP reflects renal fibrosis and predicts graft out-
come. (IV)
5. the prognostic values of α1-microalbuminuria and albuminuria in the development of
CAD. (V)
6. the impact of low-grade inflammation – measured by serum CRP – on graft function
loss. (VI)
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PATIENTS AND METHODS
1. Subjects
Part 1. Acute allograft rejection
Studies I and III
From October 1995 to November 1996 altogether 171 adult patients underwent kidney
transplantation at the Department of Surgery of Helsinki University Hospital: 155 (91%)
patients underwent the first, 12 (7%) patients the second, and 4 (2.3%) patients the third
renal transplantation. They were followed in the same hospital during the first three to four
weeks after transplantation. The 136 patients (79.5%), whose graft started functioning im-
mediately or within a few days after transplantation, and who had at least two urine samples
collected  during the first posttransplant follow-up weeks, entered the prospective study
(original papers I and III). The patients had a mean age of 42 years (range from 15 to 62).
121 patients (89%) underwent the first, 12 patients (8.8%) the second, and 3 patients (2.2%)
the third transplantation. The underlying renal diseases were diabetic nephropathy and chronic
glomerulonephritis both in 35, adult polycystic kidney disease in 18, chronic interstitial
nephritis in 9, and other kidney diseases in 39 patients. During the first 1-6 (mean 3.2)
posttransplant weeks, 30 patients (28.3%) had acute rejection, that occurred on days 8 to 37
after transplantation (mean 18.7), but 106 patients did not show any signs of rejection.The
clinical characteristics of the patients are presented in Table 1.
Study II. The original paper II consisted of a subgroup of 40 patients, (17 patients with
stable graft function and 23 patients with rejection), who during the follow-up had at least
three urine samples collected as follows: one before rejection, one within few days of
rejection and one after rejection.
Table 1. Clinical characteristics of the subjects in original papers I and III. The values are ex-
pressed as persentage or as means (SD).
Acute rejection No rejection
N 30 106
Male/Female 22/8 66/40
Age (years) 42 ± 11 47 ± 12
Primary renal disease
Diabetic nephropathy (%) 20.0 27.4
Adult polycystic renal disease (%) 20.0 17.0
Glomerulonephritis (%) 16.7 26.4
Cold ischemia time, h 23.2 ± 5.8 24.2 ± 5.5
HLA mismatch 2.48 ± 1.05 2.20 ± 1.03
Retransplantation (%) 13.3 10.4
Cadaver/living donor 29/1 105/1
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Part 2. Chronic allograft dysfunction
Studies IV-VI
A total of 479 adult patients (185 females and 294 males) underwent renal transplantation
at Helsinki University Hospital during October 1995 through December 1998. One hun-
dred and thirty patients (27%) lived in the Helsinki University Hospital District and thus
attended our follow-up. The follow-up protocol was approved by the Committee on Re-
search Ethics at the Helsinki University Hospital and included the regular clinical con-
trols, protocol biopsy at six months posttransplantation of all patients with a functioning
graft and adequate blood coagulation, and the collection of serum and 24 hour urine
samples a few days before the biopsy. Requirements for the patients who were included in
the follow-up study were (1) adequate protocol core biopsy that excluded the occurrence
of primary kidney disease, and (2) 24-hour urine samples collected at the time of biopsy.
The biopsy was considered adequate if it contained at least five (mean 9.4, range 5-20)
glomeruli. Altogether 79 cadaveric graft recipients (61%) (31 females, 48 males, mean
age 47, range from 22 to 68 years) met these selection criteria, and attended the follow-up
study, that started at the time of protocol biopsy and continued until June 2004. Within
this time, additional biopsy specimens (n=34) were obtained on clinical indications from
23 patients. Sixty-nine patients underwent their first, 9 patients their second, and 1 patient
a third renal transplantation. Nineteen patients (9 females, 10 males) belonged also to
Part 1 of this study. Five of these patients had had episode(s) of AR. The underlying
disease was diabetic nephropathy in 27, chronic glomerulonephritis in 19, adult polycyst-
ic kidney disease in 18, and other kidney diseases in 15 patients. Data on sex, age, smok-
ing habbits, height, atherosclerotic/cardiovascular disease, pretransplant diabetes, medi-
cation, HLA mismatch (AB + DR), cold ischemia time, delayed graft function, retrans-
plantation, and on infections and AR episodes which occurred during the first six post-
transplant months were obtained from medical records, or from the Finnish Kidney Dis-
ease Registry files, and are presented in Table 2.
Table 2. Clinical characteristics of the patients of original papers IV–VI at 6 months from trans-
plantation. The values are expressed as percentage or as means (SD).
N 79
Male/Female 48/31
Age (years) 47 ± 10
Primary renal disease
Diabetic nephropathy (%) 34.2
Glomerulonephritis (%) 24.0
Adult polycystic kidney disease (%) 22.8
Atherosclerotic/cardiovascular disease (%) 34.5
Smokers (%) 6.3
BMI, kg/m2 24.9 ± 0.9
Hypertension (%) 52.0
Retransplantation (%) 12.6
Donor age (years) 39.1 ± 12.9
Delayed graft function (%) 12.7
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Acute rejections (%) 20.3
Cold ischemic time, h 20.5 ± 3.7
HLA mismatch 2.27 ± 1.01
Infections during the first six postransplantation months (%) 36.7
s-cholesterol, mmol/l 6.6 ± 0.6
s-CRP, mg/l 2.4 ± 1.7
2. Urines and sera
Part 1. Acute allograft rejection
The protocol of this prospective study included the collection of 24-hour urine samples
once a week during the hospital period. Twenty-five patients (19 men, 6 females) had
delayed graft function, and excreted no urine during the first 1to 2 weeks, three patients
had no urines and ten patients (all females) with immediately functioning grafts had only
one 24-hour urine collected within the first posttransplantation weeks. Urine samples
were collected approximately once a week from 136 patients during their posttransplanta-
tion stay at the transplantation unit. In 30 patients with rejection, altogether 77 urine
samples were collected. In relation to the rejection these urine samples were as follows:
one prerejection (16 to 6 days before, n= 25 samples), one close to rejection (5 to 0 days
before, n=19 samples), and one or two postrejection (1 to 20 days after, n= 33 samples).
In 106 patients with stable graft function, 24-hour urine samples were collected as fol-
lows: approximately one week after transplantation (5 to 11 days, n= 87 samples), two to
three weeks after transplantation (11 to 23 days, n=136 samples), totalling 223 urines.
In addition, 24-hour urine samples from 33 healthy persons (21 men, 12 women, mean
age 37 years) were used to analyze reference values for urinary excretion of the investi-
gated proteins ( original papers I-III).
Part 2. Chronic allograft dysfunction
24-hour urine samples were collected from all 79 patients a few days before the protocol
biopsy, and during the follow-up period on clinical indications, and in conjunction with
rebiopsies (34 biopsies from 23 patients). Moreover, 24-hour urines were collected from
eight volunteers over 5 consecutive days to test the daily changes in the levels of urinary
PIIINP.
At the time of protocol biopsy, sera were obtained from 62 of 79 (78%) patients, and
thereafter at 12-months intervals. In addition, sera obtained from healthy persons (50
healthy blood donors, 33 men and 17 women, mean age 37.5 years, the Finnish Red
Cross, Helsinki) were used to determine the reference values of serum amino-terminal
propeptide of type III procollagen (PIIINP) and of CRP.
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3. Methods
Part 1. Acute allograft rejection
3.1. Diagnosis and treatment of rejection
Acute rejection was defined as an episode of decreased allograft function. The rejection
diagnosis was based on clinical and laboratory data, on the response to antirejection ther-
apy, and was verified with fine-needle aspiration cytology (Pasternack et al. 1973) or core
biopsy, or both. The first day of rejection was defined as the day of clinical diagnosis and
the start of antirejection therapy. Rejection episodes were routinely treated with methyl-
prednisolone (MP) (3 mg/kg) divided into four daily doses over five days. Five patients
received OKT 3 as immunosuppression induction.
3.2. Immunosuppression
All patients received triple drug therapy. A single oral dose of cyclosporine (CsA) (5 mg/
kg) was given preoperatively, azathioprine and methylprednisolone (MP) were started at
the beginning of the operation. CsA was administered at a dosage of 10 mg/kg daily and
was adjusted to maintain whole blood level at 300-400 µg/l in the first 4 weeks, azathio-
prine was initiated at 2mg/kg daily, and tapered to 1mg/kg after 2 weeks. MP dose was
initially 1 mg/kg daily, and was tapered to 0.25 mg/kg daily on the 10 th postoperative
day.
Part 2. Chronic allograft dysfunction
3.3. The regular clinical control of the patients
A protocol biopsy specimen was obtained from all 79 patients at 6 (6.1 ± 0.3) months
after transplantation. From the time of protocol biopsy, the patients were prospectively
followed until June 2004, or until they returned to dialysis or died. Within the follow-up
(mean 5.9, range 1.2–8.2 years) after transplantation, eight patients (10.1%) died, and
dialysis treatment was started in five males (6.3%). During the follow-up period, each
patient was recalled to the hospital for clinical control at 6 and 12 months, and thereafter
at 12-month intervals. Moreover, in the case of any complications they attended the out-
patient clinic and/or stayed in the hospital.
At the time of protocol biopsy, glucose tolerance test and conventional electrocardiogram
(ECG) were performed, weight and blood pressure were measured, cardiovascular com-
plications and a treatment for hypertension were recorded. Sera and 24-hour urine sam-
ples for the analyses reported in the original papers IV-VI were collected and deep-fro-
zen. Graft function tests, including serum creatinine, urea, uric acid, and 24-hour creati-
nine and urea clearances were determined. Glycaemic control was assessed by measuring
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plasma fasting glucose and GHbA1c. Plasma levels of CRP, electrolytes, parathyroid
hormone (PTH), ionized calcium, phosphate, and alkaline phosphatase, and tests for
haematological status were determined. CsA levels were determined, and the dose adjust-
ed to maintain through blood concentration in the range from 60 to 120 µg/l. Specific
urinary assays included 24-hour protein excretion, quantitative microscopy of centrifuged
morning urine specimen, and the cultivation for urinary bacteria.
3.4. Definition of the deterioration of GFR
Renal function was measured routinely by serum creatinine and 24-hour creatinine clear-
ance at 6 and 12 months after transplantation, and thereafter at 12-month intervals and
each time patients stayed in the hospital and/or when additional biopsies were taken. The
24-hour clearance data, on an average 8.0 (range 4 -11) determinations per patient, were
plotted versus time to calculate the annual change of GFR. The deterioration of GFR was
defined by an annual decrease of more than 3 ml/min/1.73 m2 (mean value).
3.5. Immunosuppression
At the time  of the protocol biopsy, all patients were treated with CsA targeting at whole
blood  CsA levels from 60 to 120 µg/l, 25 mg of azathioprine administered three times
daily, and methylprednisolone (MP) 8 to 12 mg administered daily. During the follow-up,
the MP dose was gradually tapered to 2 to 4 ( mean 3.6) mg/day; in seven patients, azathi-
oprine treatment was changed to mycophenolate (2 g/day); in one patient azathioprine
and in one patient MP treatment was stopped.
3.6. Assessment  and  treatment of hypertension
Blood pressure was measured at the time of protocol biopsy. Hypertension was defined
by supine systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg.
At that time, 72 of 79 patients (91%) used anti-hypertensive medication (36 patients had
β-blockers, 19 patients had Ca-antagonists, 13 patients had both a β-blocker and Ca-
antagonist, and 4 patients had ACE-inhibitors).
3.7. Assessment of atherosclerotic/cardiovascular disease
The presence of atherosclerotic/cardiovascular disease was based on the medical history
obtained from the medical records.
3.8.  Analysis of protocol biopsies and the estimation of interstitial fibrosis
The histological specimens were examined and graded semiquantitatively by an experi-
enced observer, who was unaware of the outcome of the patient. The specimens were
evaluated for glomerular, tubular, interstitial, and vascular (arteries, veins and arterioles)
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changes. The changes were graded from 0 to 3, where 0 represents no changes, 1 mild, 2
moderate, and 3 severe changes according to the Banff classification (Racusen et al. 1999).
Interstitial fibrosis tissue in up to 5% of cortical area was graded 0 (ci 0), fibrosis tissue in
6 to 25% of cortical area was graded mild (ci 1), in 26 to 50% of cortical area was graded
moderate (ci 2). Severe interstitial fibrosis (ci 3) consisted more than 50% of cortical
area.
3.9.  Causes of death
During the follow-up period, 8 patients died. Cardiovascular disease was a cause of death
in five patients, infection in two patients and the cancer of pancreas in one patient
3.10. Assays
I developed new assays for urinary α1M, IL-1β, TGF-β1 and for serum high- sensitivity
CRP, and determined all investigated proteins.
Interleukin-1β. Interleukin-1β in urine was measured by modified radioimmunoassay (RIA)
as follows. The polyclonal, goat IgG antibodies to human IL-1β (100 ng/tube in 0.05 M
Na-carbonate, pH 9.8) (Code AF-201-Na, R&D Systems Inc, MN, USA) were used for
the coating of the polystyrene tubes at 4 °C overnight. After washing the tubes, 0.5 ml of
the IL-1β standard  (human IL-1β, Code 201-LB-005, R&D Systems, Inc., MN, USA)
dilutions (1000 – 10 ng/l) and patients urine diluted 2-fold with phosphate-buffered saline
(PBS) containing 0.5% Tween 20 were added to tubes and incubated at 4 °C overnight to
allow IL-1β to react with surface-adsorbed antibodies, thereafter washed three times with
PBS-Tween 20. The amount of IL-1β bound to the antibodies was determined by adding
125-I-labeled IgG antibodies to IL-1β (approximately 15000 counts/tube/min) in PBS
containing 5% bovine serum albumin and 0.5% of Tween 20 to each tube. After incuba-
tion at 4 °C overnight, the tubes were washed three times with PBS-Tween 20, and count-
ed for radioactivity. All measurements were done in triplicate. A detection limit of the
assay was 10 ng/L, and an intra-assay coefficient of variation 7.2%.
Enzyme immunoassay for TGF-β1. Microtiter plates (Maxisorp, Nunc Intermed, Den-
mark) were coated with monoclonal mouse antiserum to human TGF-βs (Genzyme Diag-
nostics, Cambridge, MA, USA) 100 ng/well in 0.05 M Na-carbonate buffer, pH 9.2 over-
night at 4 °C. After washing the wells with 0.05 M phosphate-buffered saline (PBS), pH
7.3, containing 0.05% Tween 20, 100 ml of acid-activated (0.1 N HCl, 10 min, at room
temperature) and neutralized standard dilutions ( human TGF-β1, R&D Systems, Inc.,
MN, USA) and urine samples were added to the wells and incubated overnight at 4 °C.
The unbound material was removed by washing with PBS-Tween 20, and 100 ml of
antibodies to human TGF-β1 (Code 27.283.29 from Jansen Biochimica, Belgium) conju-
gated with alkaline phosphatase were pipetted to the wells 1000-fold diluted and incubat-
ed for 2 hours at 37 °C. After washing, the amount of alkaline phosphatase fixed to the
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tubes was determined in diethanolamine-magnesium chloride buffer, pH 10.0, using p-
nitrophenylphosphate as substrate by incubation for 1 hour at room temperature. The
absorbance of the liberated p-nitrophenolate was measured at 405 nm with  a microtitra-
tion plate reader (SLT, Labinstruments, Vienna, Austria). The detection limit of the assay
was 10 ng/L. The intra-assay coefficient of variation was 5.9%.
Other methods. Details of the methods are described in the original papers. Serum and
urine creatinine levels were measured by modified Jaffe reaction by using an Hitachi 911
E Automatic Analyzer and SYS 2 BM Hitachi reagents (Behringer Mannheim, Germa-
ny). Renal function was assessed by 24-hour creatinine clearance. Plasma samples for
cholesterol determinations were obtained after overnight fasting. Plasma cholesterol was
determined enzymatically by using commercially available method (Boehringer Mannhe-
im, Mannheim, Germany). HLA typing was performed by a standard two-stage cytotox-
icity with different antisera defining 11 A-locus, 20 B-locus, and eight DR specificities.
Radioimmunoassays (RIA) were used to measure urinary albumin (Albumin RIA, Phar-
macia, Sweden) (Studies I-V), α1-microglobulin (Studies I,V) and urinary and serum
amino-terminal propeptide of type III procollagen (Study IV). Serum C-reactive protein
was measured by immunoturbidimetry (Study II) and by RIA (Study VI).
Enzyme immunoassays (EIA) were used to measure urinary interleukin-1 receptor antag-
onist (IL-1ra) (Study II), soluble intercellular adhesion molecule-1 (sICAM-1), and inter-
leukin-2 receptor (sIL-2R) (Study III), and fluorescence polarization immunoassay to
measure blood CsA levels (Study IV). Molecular weight estimation of urinary sICAM-1
and staining for ICAM-1 in the urinary sediment are described in Study III. Estimation of
interstitial fibrosis in kidney biopsies is described in Study IV, and immunofluorescence
staining for CRP and C3 in Study VI.
4. Statistical analyses
All data are expressed as mean ± SD unless otherwise stated. Differences between group
means were assessed with analysis of variance (ANOVA), and with Mann-Whitney U-
test. Simple linear regression analyses were used to study relationships between two var-
iables, non-normally distributed variables after logarithmic transformation. Differences
in observed frequences between groups were tested with Pearson´s Chi-square test. Sen-
sitivity, specificity, and predictive values were calculated as described by Vecchio (1966).
A probability of less than 0.05 was considered statistically significant.
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RESULTS
Part 1. Acute allograft rejection
1. Incidence of early acute rejection episodes (I, II, III)
During the follow-up period (mean 3.2 posttransplantation weeks), 30 patients (22%) (22
men and 8 women) had AR episode(s) whereas 106 patients (66 men and 40 women) did
not show any signs of rejection. Rejection occurred on days 8 to 37 (mean 18.7) after
transplantation. Patients who had AR had worse HLA mismatch (2.48 ± 1.05) than pa-
tients with stable graft function (2.20 ± 1.03) (p<0.05).
2. Urinary excretion of α1-microglobulin during first posttransplanta-
tion weeks in renal transplant recipients with and without AR
Averagely one week after transplantation, the mean α1M/creatinine ratio of transplanted
patients was over 50 times higher than that of the healthy controls (16.9 ± 7.9 vs. 0.27 ±
0.15 mg/mmol), and the urinary excretion of α1M was associated with cold ischemia time
(r = 0.347, p < 0.001). At that time, no significant difference in the urinary excretion of
α1M was noticed between patients who developed AR and those who did not (18.9 ± 7.2
mg/mmol vs. 16.2 ± 8.1 mg/mmol, NS). During the second postransplantation week,
α1M/creatinine ratio decreased in 77 of 87 patients (88.5%) with stable graft function,
but only in 4 of 28 (14.2%) of those with acute rejection (p<0.01). On the other hand, in
patients with AR  the α1M/creatinine ratio between first and second urine samples in-
creased in 20 of 27 patients (74.1%). Averagely two weeks after transplantation, the mean
α1M/creatinine ratio was significantly higher in patients who developed AR than in those
who did not (Table 3). After the first posttransplantation week, the decreasing α1M/creat-
inine ratio had 95% positive predictive value in detecting nonrejecting patients, and the
increasing ratio had 71% predictive value in detecting rejecting patients.
Table 3. Urinary α1M/creatinine ratios in patients with and without AR at various times after
renal transplantation.
Group Days after Number of urines α1M/creatinine ratio,
transplantation, mean mg/mmol, mean
(range) (range)
Acute rejection 8.4 (  5 – 11) 28 19 (5 – 39)
15.6 (12 – 20) 29 22 (5 – 45)
24.1 (17 – 37) 18 26 (8 – 45)
No rejection 8.5 ( 5 – 10) 87 16 (3 – 34)
14.7 (11 – 21) 92 10 (2 – 40)
19.8 (15 – 23) 44 8 (2 – 40)
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3. Urinary excretion of IL-1β and IL-1ra in rejecting and non-rejecting
transplanted patients
During the first posttransplantation weeks, the patients who developed rejection excreted
higher amounts of IL-1β (mean 55 ng/24 hour vs. 30 ng/24 hour) and lower amounts of
IL-1ra (450 ng/24 hour vs. 720 ng/24 hour). Consequently, the mean IL-1ra/IL-1β ratio
was signficantly lower in rejecting patients (mean ± SD, 9.5 ± 15.7 vs. 47 ± 62 , p<0.05).
Moreover, the IL-1ra/IL-1β ratio decreased during rejection, and was lower at the time of
rejection (2.8 ± 2.9) than before (mean 13.3 ± 23.5) or after (mean 12.5 ±  20.8) rejection.
On the contrary, in patients with stable graft function the IL-1ra/IL-1β ratio remained
rather constant during the entire posttransplant phase: mean (median) IL-1ra/IL-1β ratios
42 (16); 51 (19); and 48 (17) on an average 1, 2, and 3 weeks after transplantation.
4. Urinary excretion of sICAM-1 during first postransplantation weeks
in patients with and without AR
Approximately one week after transplantation, the mean sICAM-1/creatinine ratios of
both rejecting (316 ng/mmol) and nonrejecting (293 ng/mmol) patients were only slightly
higher than that of the healthy subjects (167 ng/mmol), and decreased in nonrejecting
patients to the mean value of 225 ng/mmol (NS) during the following week. On the con-
trary, few days before the clinical rejection the mean sICAM-1/creatinine ratio increased
to the mean value of 793 ng/mmol (p<0.01 compared to the first week value) in patients
with AR. After the initiation of antirejection therapy, the mean sICAM-1/creatinine ratio
decreased within two weeks to the level of healthy subjects (mean 178 ng/mmol).
In the urinary sediment of rejecting patients, ICAM-1-positivity was demonstrated ap-
proximately in 20% of the tubular epithelial cells, and in 25% of the activated macro-
phages, but not at all in the leukocytes. On the contrary, in nonrejecting patients the urines
did not contain macrophages or lymphocytes, but contained ICAM-1-negative surface
epithelial cells of the lower urinary tract and granulocytes. These findings suggest that in
healthy persons and in nonrejecting patients urinary sICAM-1 probably originates from
the vascular endothelial cells, whereas in rejecting patients it may be produced also by
tubular epithelial cells and by activated macrophages.
Part 2. Chronic allograft dysfunction
1. The outcome of patients
During the follow-up period (mean 5.9 years), GFR deteriorated in 21 patients (26.6%)
(progressors), and improved or remained unchanged in 58 patients (73.4%) (non-pro-
gressors), eight patients (10%) with a functioning graft died and dialysis treatment was
started in five patients. At six  months from transplantation, mean values of serum creat-
inine and of GFR were 125 µmol/l and 54 ml/min/1.73 m2 in the progressors, and 116
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µmol/l and 57 ml/min/1.73 m2 in the non-progressors. At the end of the follow-up, mean
serum creatinine and GFR were 422 µmol/l and 25 ml/min/1.73 m2 in the progressors,
and 88 µmol/l and 76 ml/min/1.73 m2 in the non-progressors (Table 4).
Table 4. Clinical characteristics of progressors and non-progressors at six months from trans-
plantation and at the end of follow-up. The values are expressed as percentage or as
means (SD).
Clinical characteristics Progressors Non-progressors p-value
Patient characteristic
N 21* 58**
Males, n (%) 15 (73.7) 33 (56.9) NS
Age, year 43.1 (11.4) 48.1 (9.7) NS
Atherosclerotic/cardio-
vascular disease n (%) 11 (52.4) 16 (27.6) < 0.05
Diabetes, n (%) 6 (28.5) 21 (36.2) NS
Hypertension, n (%) 14 (66.7) 27 (46.6) NS
s-cholesterol, mmol/l 6.7 (0.6) 6.6 (0.7) NS
s-CRP, mg/l 5.3 (2.9) 1.4 (1.2) < 0.05
BMI, kg/m2 25.4 (0.9) 24.7 (0.8) NS
s-creatinine, µmol/l 125 (31) 116 (24) NS
GFR, ml/min/1.73 m2  54 (16) 57 (14) NS
Histopathological changes,
n (%) 14 (66.6) 25 (43.1) NS
Transplantation associated data
Donor age, years 41.4 (16.1) 38.3 (8.4) NS
Delayed graft function 3 (14.3) 7 (12.1) NS
Acute rejections 7 (33.3) 9 (15.5) < 0.05
Cold ischemia time, h 21.6 (4.1) 20.1 (3.5) NS
HLA mismatch 2.38 (0.86) 2.23 (1.05) NS
Retransplantation 7 (33.3) 3 (5.2) < 0.01
At the end of follow-up
Follow-up, months 64.2 (25.6) 73.7 (13.7) < 0.05
s-creatinine, µmol/l 422 (395) 88 (24) < 0.01
GFR, ml/min/1.73 m2 25 (18) 76 (18) < 0.01
** During the follow-up three patients (14.3%) died
** During the follow-up five patients (8.6%) died
NS = not significant
The patients who developed CAD had higher frequency of atherosclerotic/cardiovascular disease,
acute rejections and retransplantations, and higher concentration of serum CRP, whereas no differ-
ences between the patients were found in the frequency of diabetes and hypertension, donor age,
delayed graft function, cold ischemia time, or HLA mismatch.
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2. Histopathological changes in 6 month protocol biopsy as the marker
of graft outcome (IV)
At 6-month protocol biopsy specimens, there were no or only minor histopathological
changes in 40 patients (50.6%) (Group 1), and mild to moderate changes (grade ≥ 2) in 39
patients (49.4%) (Group 2). The clinical data of the patients are presented in Table 5. At
the time of biopsy, all  Group 1 patients, but only 17 (43.6%) of  Group 2 patients had
serum creatinine less than 120 mmol/l (internationally accepted limit for good graft func-
tion). Histopathological changes were present in more than one third of patients with
good graft function. During the follow-up period (mean 71 months), GFR deteriorated in
7 (17.5%) of Group 1 patients, and in 14 (35.9%) of Group 2 patients (p< 0.01).
Special attention was paid to the extent of interstitial fibrosis in the protocol biopsy spec-
imens. No interstitial fibrosis (ci 0) was found in 35 patients (44%), mild fibrosis (ci 1)
was recorded in 29 patients (37%), and moderate fibrosis (ci 2) in 15 patients (19%).
None of the patients showed severe (ci 3) interstitial fibrosis.
At the start of follow-up, there was no significant difference in the renal function between
the patients with and without interstitial fibrosis. During the follow-up, the mean GFR
increased in patients with no fibrosis, and decreased in the patients with mild or moderate
fibrosis (Table 6).
Table 5. Clinical data of the patients. Patients are divided into groups on the basis of the histo-
logical findings in 6-month biopsies. Group 1 patients had no or minor histological
changes, Group 2 patients had mild or moderate histological changes.
Clinical data Group 1 Group 2 p-value*
N 40** 39***
Males 52% 72% NS
Patient age,years 47.0 (10.3) 46.8 (10.5) NS
Atherosclerotic/cardiovascular disease 33% 36% NS
Diabetes 33% 36% NS
Hypertension 53% 51% NS
s-cholesterol, mmol/l 6.6 (0.5) 6.7 (0.7) NS
s-CRP, mg/l 2.1 (1.8) 2.8 (1.7) NS
s-creatinine, µmol/l 108 (20) 129 (32) NS
s-creatinine<120µmol/l 100% 44% <0.01
BMI, kg/m2 24.5 (0.9) 25.3 (0.8) NS
GFR, ml/min/1.73 m2 62 (13) 50 (16) NS
Donor age, years 35.2 (16.4) 43.1 (8.1) < 0.05
Delayed graft function 7.5% 17.9% < 0.05
Acute rejections 20% 20% NS
Cold ischemia time, h 20.4 (3.8) 20.6 (3.6) NS
HLA mismatch 2.10 (1.01) 2.44 (1.02) < 0.05
Retransplantation 7.5% 17.9% < 0.05
*** Comparison between Groups 1 and 2
*** During follow-up, three of the patients died
*** During follow-up, five of the patients died
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Table 6. Serum creatinine and GFR at the start and at the end of the follow-up (mean, SD) in the
patient groups. Patients are divided into groups on the basis of the extent of interstitial
fibrosis (ci) in 6 month biopsy specimens. The extent of interstitial fibrosis was graded
0, mild (ci1), and moderate (ci2).
Interstitial fibrosis (ci) Follow-up (months) s-creatinine, µmol/l GFR, ml/min/1.73 m2
(Number of patients) At start At end At start At end
0 (n=35) 77 (12) 110 (17) 101 (20) 60 (11) 79 (17)
1 (n=29) 69 (20) 122 (28) 171 (99)* 58 (15) 53 (24)*
2 (n=15) 61 (26) 122 (31) 365 (347)* 50 (18) 40 (28)*
* p< 0.05, compared with the patients with no fibrosis
3. Urinary excretion of PIIINP at 6 months from transplantation as the
marker of graft outcome (IV)
The mean urinary PIIINP/creatinine ratio was lower in patients with no fibrosis ( mean ±
SD, 56 ± 47 ng/mmol) than in the healthy persons (77 ± 23 ng/mmol, p< 0.05) or in the
patients with mild (160 ± 112 ng/mmol) or moderate (262 ± 229 ng/mmol) interstitial
fibrosis (p< 0.01) (Fig. 1). There was a close correlation (r= 0.410, p< 0.001) between the
urinary PIIINP/creatinine ratio and the extent of interstitial fibrosis. A PIIINP/creatinine
Figure 1. Urinary ratios of PIIINP/creatinine
(in nanograms per millimole) in patient groups
with interstitial fibrosis graded from 0 to 2.
Patients whose GFR decreased during the fol-
low-up (filled circles) .
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ratio less than 100 ng/mmol (i.e. mean + SD of healthy persons) was found in 83% of
patients without interstitial fibrosis but only in 16% of patients with interstitial fibrosis
(p< 0.01). At 6 month from transplantation, the mean urinary PIIINP/creatinine ratio was
significantly higher in those patients who developed CAD (220 ±  200 ng/mmol) than in
those who did not (102 ± 88 ng/mmol, p< 0.01) (Table 7). During the follow-up, PIIINP/
creatinine ratios of individual patients remained rather constant. Low ratios were associ-
ated with stable or increasing GFR, whereas high ratios were associated with decreasing
GFR. GFR decreased in 42% of the patients with a PIIINP/creatinine ratio greater than
100 ng/mmol, but only in 8% of patients with this ratio less than 100 ng/mmol (p<0.01)
(Fig. 1).
4. The urinary excretion of TGF-β1 at 6 month from transplantation in
progressors, non-progressors, and in the healthy subjects (IV)
At six month from transplantation, the renal transplanted patients excreted significantly
higher amounts of TGF-β1 than the healthy subjects (mean + SD; 62 ± 34 ng/mmol vs. 9
± 8 ng/mmol, p<0.01). There were close correlations between urinary TGF-β1 and inter-
stitial fibrosis  (r= 0.392, p<0.001), between TGF-β1 and PIIINP (r = 0.585, p< 0.001)
and between TGF-β1 and α1M (r = 0.638, p<0.001). The mean TGF-β1/creatinine ratio
was significantly higher in the progressors than in the non-progressors (107 ± 47 vs. 45 ±
40 ng/mmol, p< 0.01) (Table 7).
Table 7. The urinary excretion of PIIINP, TGF-β1, α1M and albumin at 6 month from transplan-
tation in the progressors, non-progressors, and in the healthy subjects. The values are
expressed as mean (range) protein/creatinine ratios.
Urinary protein Progressors Non-progressors Healthy subjects
(n=21) (n=58) (n=33)
PIIINP, ng/mmol 220 (50-868) 102 (10-274)* 77 (20-153)
TGF-β1, ng/mmol 107 (15-263) 45 (1-178)** 9 (1-34)
α1M, mg/mmol 13.8 (2-29) 3.3 (0.4-12)** 0.3 (0.04-0.7)
Albumin, mg/mmol 60 (1-394) 5.4 (0.5-71)** 0.3 (0.03-0.8)
* p< 0.05,  ** p< 0.01 compared to the progressors
5. The urinary excretion of α1-microglobulin at 6 months from
transplantation as the marker of graft outcome.
At 6 months from transplantation, the mean α1M/creatinine ratio was more than four
times higher in the progressors than in the non-progressors ( mean ± SD, 13.8 ± 6.2 vs.
3.3 ± 2.1, p< 0.01) (Table 7). During follow-up, GFR deteriorated in 20 of 33 patients
(60%) with α1M/creatinine ratio greater than 5 mg/mmol ( mean + SD of the normoalbu-
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minuric patients), but only in one of 46 patients (2%) with this ratio less than 5 mg/mmol
(p< 0.01) (Fig. 2). This gives α1M/creatinine ratio greater than 5 mg/mmol 95% sensitiv-
ity, 78% specificity, and 60% positive predictive value to detect patients whose GFR will
deteriorate during follow-up. The 33 patients with α1M/creatinine greater than 5 mg/
mmol had higher TGF-β1/creatinine ratio ( 92 ± 48 vs. 40 ± 27 ng/mmol, p< 0.01), more
frequently histological changes ( 63% vs. 39%, p< 0.05), reduced renal function ( s-
creatinine > 120 µmol/L; 45% vs. 15%, p< 0.01), and they had had more frequently acute
rejections ( 33% vs. 11%, p< 0.01).
Figure 2. α1-Microglobulin (α1M)/creatinine
ratio (mg/mmol) 6 months after transplanta-
tion in patient groups divided on the basis
of albuminuria. Group A: normoalbuminuria.
Group B: microalbuminuria. Group C: mac-
roalbuminuria. Patients whose GFR decreased
during follow-up (filled circles).
6. The urinary excretion of albumin at six months from transplantation
as the marker of graft outcome
At six months from transplantation, renal transplant recipients excreted about 50 times
more albumin than the healthy subjects ( 201 ± 281 vs. 4.4 ± 2.9 mg/24 hour; p< 0.01): 46
patients (58%) had normoalbuminuria, 25 (32%) had microalbuminuria , and 8 patients
(10%) had macroalbuminuria (Table 8). There was no significant difference in the mean
values of serum creatinine or of GFR between these groups  (Table 8). Histopathological
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changes were present in 35% of normoalbuminuric, in 60 % of microalbuminuric, and in
all of macroalbuminuric patients. There was no significant difference in the grade of
histological changes between normo- and microalbuminuric patients, whereas macroalbu-
minuric patients had more severe histopathological changes: six patients (75%) were clas-
sified as having chronic allograft nephropathy (CAN) (Table 8).
During the follow-up, GFR deteriorated in five of normoalbuminuric patients (11%), in 9
of micro-albuminuric patients (36%), and in 7 of macroalbuminuric patients (88%) (Fig.
3). Dialysis treatment was started in one microalbuminuric and in four macroalbuminuric
patients. At the end of the follow-up period, the mean values of s-creatinine in normo-,
micro- and macroalbuminuric patients were 106, 143, and 690 µmol/l and those of GFR
76, 50, and 22 ml/min/1.73 m2, respectively (Table 8).
Sensitivity, specificity and positive predictive value of microalbuminuria to detect pa-
tients whose GFR will deteriorate were 76%, 70%, and 46%, respectively. When the cut-
off value of 100 mg/24 h was used, sensitivity, specificity, and positive predictive values
were 48%, 93% and 71%, respectively.
Figure 3. Albuminuria at 6 months after trans-
plantation. Group A: normoalbuminuria (urinary
albumin <30 mg/24 h). Group B: microalbu-
minuria (urinary albumin 30–300 mg/24 h).
Group C: macroalbuminuria (urinary albumin
>300 mg/24 h). Patients whose glomerular fil-
tration rate (GFR) deteriorated during follow-
up (filled circles).
48
Table 8. Clinical data of the patients divided into groups on the basis of albuminuria. Group A:
normoalbuminuria (urinary albumin < 30 mg/24 h), Group B: microalbuminuria
(urinary albumin 30-300 mg/24 h), Group C: macroalbuminuria (urinary albumin > 300
mg/24 h). Values are expressed as mean (SD) or number (percentages) of patients.
Group A Group B Group C
At six month after transplantation
N 46 (58%) 25 (32%) 8 (10%)
Males 24 (52%) 16 (64%) 8 (100%)
Patient age 47.5 (10.4) 46.2 (12.5) 46.9 (10.7)
Albumin, mg/24 h 13 (7) 88 (65)** 1637 (1881)
Hypertension 20 (43%) 13 (52%) 7 (88%)
Diabetes 11 (24%) 14 (56%)** 2 (25%)
Acute rejections 6 (13%) 8 (32%)* 2 (25%)*
Histological changes 16 (35%) 15 (60%)** 8 (100%)
Grade of histological changes 1.7 (1.5) 2.3 (2.2) 4.8 (3.1)
BMI, kg/m2 24.7 (0.9) 25.2 (0.8) 25.1 (0.7)
s-creatinine, µmol/l 115 (26) 129 (30) 134 (34)
s-creat. > 120 µmol/l 4 (9%) 11 (44%)** 7 (88%)
GFR, ml/min/1.73 m2 59 (16) 52 (15) 55 (18)
s-cholesterol, mmol/l 6.7 (0.5) 6.6 (0.7) 6.6 (0.6)
At the end of follow-up
Follow-up, months 73.1 (14.2) 69.7 (19.2) 65.1 (21.3)
s-creatinine 106 (35) 143 (65) 690 (513)
GFR, ml/min/1.73 m2 76 (20) 50 (22)** 22 (25)
GFR deteriorated 5 (11%) 9 (36%)** 7 (88%)
Annual change of GFR,ml/min/1.73 m2 3.7 (2.1) –1.0 (1.1)** -6.7 (4.9)
Dialysis treatment started 0 (0%) 1 (4%)* 4 (50%)*
* p< 0.05 compared to Group A patients;  ** p< 0.05 compared to Group A and Group B patients
7. Serum concentration of CRP during post-biopsy follow-up as the
marker of graft outcome (VI)
Since chronic histopathological changes may affect long-term graft function, only those
40 patients who had no or minor histopathological changes in the protocol biopsy were
included in further follow-up to study the relationship between the concentration of CRP
and the changes of GFR. During follow-up, baseline CRP was determined averagely 4.1
(3-7) times per patient, and the patients were divided into 2 groups on the basis of CRP
concentration. Group A consisted of 23 patients with normal CRP levels (1.12 ± 0.27 mg/
l), and Group B consisted of 17 patients with increased levels (4.16 ± 1.67 mg/l). During
the follow-up, GFR improved or remained the same in all Group A patients, but de-
creased in 7 (41%) of Group B patients (p<0.01). In Group B patients, mean CRP con-
centration correlated inversely with the annual change of GFR (r=-0.688, p<0.01).
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DISCUSSION
1. Urinary IL-1β/IL-1ra ratio as the indicator of acute rejection
This study shows that patients who produce high amounts of IL-1ra in relation to IL-1β
are less prone to acute rejection than patients  with low IL-1ra/IL-1β ratios. This finding
agrees with the earlier observations suggesting that the balance between IL-1ra and IL-1
is important in the regulation of the inflammatory responses (Bevan and Raynes 1991,
Ferretti et al. 1994, Dinarello 2000). In many inflammatory diseases, both in humans and
in animals, a high concentration of endogenous IL-1ra or administration of exogenous IL-
1ra have been shown to relate to shorter recovery time or to reduced mortality (Ohlsson et
al. 1990, Ferretti et al. 1994,  McCarthy et al. 1996) or to protect patients from the out-
break of disease (Palmer et al. 2003). In mice, the transplant survival of corneal allograft
recipients has been prolonged by the topical application of IL-1ra on cornea (Dana et al.
1997). In addition, the deletion of IL-1β or blocking its activity by IL-1ra treatment has
been shown to be of therapeutic benefit in many IL-1-induced inflammatory diseases,
such as in progressive phases of experimental and human glomerulonephritis (Lan et al.
1993, 1995, Nicolic-Paterson et al. 1994, Tang et al. 1994, Karkar et al. 1995), or athero-
sclerosis (Kirii et al. 2003). The findings of this study suggest that blocking of IL-1β
activity by IL-1ra treatment may be of therapeutic benefit also in renal transplanted
patients.
2. Genetic aspects of the production of IL-1ra and of IL-1β
Because the expression of IL-1ra and IL-1β is stimulated by common factors, it was dis-
cussed in Study II that the divergent responses to the same stimuli may be genetically
determined. The IL-1 gene family codes IL-1β and IL-1ra, which both have at least two
biallelic polymorphisms. The high secretion of IL-1β has been shown to be associated
with a TagI polymorphism in the human IL-1β gene, and suggested to play an important
role in the pathogenesis of type 1diabetes (Pociot et al. 1992). On the other hand, the
polymorphism within IL-1ra gene has been shown to determine the amount of IL-1ra an
individual can produce; carriage of allele 2 of the IL-1ra gene to be associated with the
decreased production of IL-1ra (Tountas et al. 1999). This polymorphism has been found
to be significantly overexpressed in patients with inflammatory and autoimmune diseases
(Hurme et al. 1998), coronary artery disease (Francis et al. 1999), ulcerative colitis (Toun-
tas et al. 1999), kidney failure in type 2 diabetics (Lee et al. 2004), and it has been sug-
gested to contribute to susceptibility to nephropathia epidemica in Puumala virus infected
patients (Mäkelä et al. 2001). The results of this thesis (Study II) suggest that this poly-
morphism may also expose the renal transplant recipients to AR.
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3. The possible role of imbalanced IL-1β/IL-1ra ratio in the
development of CAD
IL-1β has been shown to promote interstitial fibrosis by inducing proximal tubular cell
injury, growth inhibition, extracellular matrix protein production and α-smooth muscle
cell expression (Vesey et al. 2002). Moreover, IL-1β inhibits proximal tubular epithelial
cell proliferation and induces in a dose-dependent manner proximal tubular epithelial cell
differentiation to myofibroblasts (Fan et al. 2001, Vesey et al. 2002). This differentiation
has been shown to be completely inhibited by IL-1ra (Fan et al. 2001). These findings
together with the finding that the  appearance of myofibroblasts at regions of interstitial
injury correlates strongly with interstitial injury and with CAD (Ng et al. 1998) suggest
that the increased IL-1β/IL-1ra ratio may exposure the graft also to the progressive inter-
stitial fibrosis and to CAD.
4. Urinary excretion of α1-microglobulin in the follow-up of renal
transplanted patients
4.1 Urinary α1M as the marker of ischemia-induced injury
Study I shows that averagely one week after transplantation the mean α1M/creatinine
ratio in transplant recipients was about 60-fold higher than that of the healthy subjects. At
that time the urinary excretion of α1M correlated with the duration of cold ischemia and
was suggested to reflect ischemia induced injury. The mean α1M/creatinine ratios were
about the same in patients with stable graft function and in those who later developed
rejection. In patients with uncomplicated posttransplantation course the ratio decreased.
The decrease of α1M/creatinine ratio in consequtively collected urine samples thus indi-
cates recovering tubular reabsorption capacity and rules out complications.
4.2. Urinary α1M as the indicator of acute rejection
The results of Study I show that the α1M/creatinine ratio during the first posttransplanta-
tion week serves as the measure of ischemia- induced injury, thereafter the decrease of
α1M/creatinine ratio in consequtively collected urine samples indicates recovering tubu-
lar function and rules out rejection, whereas the increase of α1M/creatinine ratio signals
acute rejection or other complications.
4.3.  Urinary α1M as the predictor of graft outcome
On the basis of the results of Study I, it can be estimated that in patients with uncomplicat-
ed posttransplantation course the urinary excretion of α1M will reach the normal level
about 2.5 months after transplantation. However, at 6 months from transplantation, the
mean urinary α1M/creatinine ratio of all transplanted patients was still 20 times higher
than that of the healthy subjects and correlated closely with TGF-β1/creatinine and PII-
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INP/creatinine ratios ( Study IV). These findings suggest the occurrence of persistent or
prolonged injury in the majority of patients. Moreover, the finding that during the follow-
up period graft function deteriorated in 61% of patients who excreted high amounts of
α1M but only in 2% of patients who excreted low amounts suggests that the magnitude of
the injury, measured by the increased urinary excretion of α1M, is an important indicator
of developing CAD.
Ischemia induces, in addition to glomerular and tubular injury, also the apoptotic death of
tubular epithelial cells (Schumer et al. 1992, Matsuno et al. 1994, Nogae et al. 1998). In
the mouse model, the intensity of apoptosis was associated with the duration of cold
ischemia (Nogae et al. 1998). The recovery from the apoptotic cell death was  reported to
take several weeks (Shoskes and Halloran 1996). These findings suggest that the con-
stantly high or increasing α1M/creatinine ratios found in Study V may be a marker of
apoptotic proximal tubular epithelial cell death.
Laine et al. (1997) suggested that apoptotic tubular epithelial cell death may play an
important role in the development of CAD. This assumption has been later confirmed by
several studies showing that both the apoptotic death of proximal tubular epithelial cells
(Zeisberg et al. 2001, Yang and Liu 2001, Razzaque et al. 2002) or their differentiation to
myofibroblasts (Herzlinger 2002, Iwano et al. 2002, Yang and Liu 2002, Robertson et al.
2004) associate with the progression of tubular atrophy, interstitial fibrosis, and with the
development of CAD. The findings that intraepithelial T-cells recruited to the renal
tubules during AR can present TGF-β and induce adjacent tubular epithelial cells to trans-
form to proliferating fibroblasts offered the direct link between AR and CAD (Robertson
et al. 2004).
The major findings of this thesis are the associations between the increase of urinary
excretion of α1M and AR (Study I) and between high urinary excretion of α1M at six
months from transplantation and poor long-term graft outcome (Study V). The latter find-
ing is consistent with the finding of  Mazzali et al. (1999) who reported high urinary
levels of α1M to be indicative for CAD. At one week after transplantation, the urinary
excretion of α1M correlated with the duration of cold ischemia: it decreased in patients
with uncomplicated posttransplantation course but increased in patients developing AR
(Study I). At 6 months from transplantation, urinary concentration of α1M correlated
closely with PIIINP, as did concentrations of α1M and TGF-β1(Study IV). The increased
urinary excretion of α1M may be due to the disturbed tubular reabsorption capacity but it
may also be due to the decreased number of reabsorbing cells. The observed correlations
between urinary α1M and TGF-β1 and between a1M and  PIIINP are consistent with the
finding that TGF-β1 alone or together with epidermal growth factor can promote epithe-
lial-myofibroblast transdifferentiation (Okada et al. 1997, Fan et al. 1999, 2001), and
suggest for the increased urinary excretions of both α1M and PIIINP to be - at least partly
- due to this transdifferentiation. The association between the high urinary excretion of
α1M and poor graft outcome (Study V) suggests that the measurement of urinary excre-
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tion of  α1M can be used as an early measure of the development of CAD in renal trans-
plant recipients.
5. Urinary amino-terminal propeptide of type III procollagen (PIIINP)
as the indicator of CAD
Interstitial matrix is predominantly composed of type I and III collagens, fibronectin, and
heparan sulfate proteoglycans (Vleming et al. 1995, Eddy 1996, Abo-Zenah et al. 2002).
The extent of interstitial fibrosis or of collagen I and III in protocol biopsy specimens has
been shown to predict long-term graft function in renal transplanted patients (Nicholsson
et al. 1996, 1999 a, Cuhani et al. 1999, Bakker et al. 2003, Grimm et al. 2003), and
increased circulating levels of PIIINP to reflect the extent of fibrosis in many fibrotic
diseases (Low et al. 1983, Frei et al. 1984).
 In this study it was revealed that urinary excretion of PIIINP correlates with the extent of
renal interstitial fibrosis, with urinary excretions of TGF-β1 and of α1M, and that  pa-
tients with elevated levels of urinary PIIINP develop CAD more frequently than those
with normal levels. The  measurement of urinary PIIINP may thus  prove useful in the
monitoring of fibrotic processes in renal transplant recipients and in the early detection of
patients at high risk of developing CAD.
Rodemann and Muller (1991) showed that fibroblasts from fibrotic kidneys synthesised
four to five times more collagen per cell than the fibroblasts from normal kidney, and
suggested that the renal mileau determines whether fibroblasts produce collagen or not.
Recent studies (Herzlinger 2002, Iwano et al. 2002) have confirmed this assumption.
Fibrosis is a complex process which include inflammatory cell infiltration, and prolifera-
tion of fibroblasts and myofibroblasts. Moreover, damaged and cytokine-stimulated renal
tubular epithelial cells differentiate to myofibroblasts through epithelial-mesenchymal
conversion. During the renal fibrosis, majority of fibroblasts have been shown to origi-
nate from renal tubular epithelial cells (Iwano et al. 2002, Lan 2003, Robertson et al.
2004). The tubular epithelial cell transformation results in increased number of interstitial
fibroblasts, in the increased synthesis and deposition of type I and III collagens, and in
advancing renal dysfunction and failing (Herzlinger 2002, Iwano et al. 2002), and presents
a direct link between tubular atrophy and concurrent interstitial fibrosis (Robertson et al.
2004).
The correlation that was found between urinary  α1M and TGF-β1 in this thesis suggests
the role of TGF-β1 in the injury or in the loss of tubular epithelial cells and consequently
in increased urinary α1M. There is lots of evidence that TGF-β1 takes part in renal fibro-
sis (Roberts et al. 1986, Border and Noble 1994, Yamamoto et al. 1994, Shihab et al.
1995, Sharma et al. 1996, Mozes et al. 1999). Increased expression of TGF-β1 has been
shown to correlate with the increased synthesis of type I and III collagens, with the extent
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of interstitial fibrosis, with a more rapid decline in renal function, and with poor long-
term allograft survival (Yamamoto et al. 1994, Sharma et al. 1996, Nicholson et al. 1999
a,b, Cuhaci et al. 1999).
The results of this thesis (Studies IV and V) show increased urinary α1M to associate
with urinary TGF-β1, PIIINP, and with poor long-term outcome. This suggests that the
measurements of urinary excretion of α1M and of PIIINP could be used as the noninva-
sive indicator of the loss of tubular epithelial cells, of renal fibrosis and of graft long-term
outcome.
6. Albuminuria as the indicator of CAD
The increased urinary excretion of albumin is a marker of glomerular damage.  In addi-
tion, albumin acts directly or indirectly on tubular cells and elicits a tubular cell response
which promotes tubulointerstitial inflammation. The infiltrating interstitial macrophages
and T-lymphocytes have an important role in the progression of glomerulosclerosis (Dia-
mond et al. 1992). Numerous recent studies indicate that he accumulation of albumin in
proximal tubular lumen promotes tubulointerstitial inflammation and initiates the fibrotic
processes leading to CAD (Eddy 1996, Yard et al. 2001, Eddy 2004). In fact, the close
association found between albuminuria and declining transplant function supports this
assumption (Hohage et al. 1997, Braun et al. 2001, Roodnat et al. 2001). In this study
urinary excretion of albumin at 6 months after transplantation was found to correlate with
the annual changes of GFR (Study V). In addition, at that time, histopathological changes
in all macroalbuminuric patients were found. This suggests that macroalbuminuria does
not develop until at the late phases of CAN, and that it cannot be used as the early indica-
tor of developing CAD. On the other hand, microalbuminuria indicates elevated risk of
CAD.
7. Elevated posttransplant serum CRP indicates risk for CAD
During post-biopsy follow-up, low-grade systemic inflammation was found to be associ-
ated with impairment of graft function (Study VI). It can be concluded that patients with
elevated CRP, are  more prone to manifest inflammation and to develop CAD, and that
increased posttransplantation CRP indicates a risk for CAD.
Elevated CRP appears to indicate a risk for renal function loss in non-diabetic population
(Stuveling et al. 2003), elevated pretransplant CRP a risk for acute rejection (Perez et al.
2000, Lauzurica et al. 2002) and CAD (Fink et al. 2002). Lauzurica et al. (2002) found,
averagely five years after transplantation, higher serum creatinine levels in those recipi-
ents who had had high pretransplant CRP levels and suggested elevated pretransplant
CRP to predict poor allograft outcome. On the other hand, Sezer et al. (2002) did not find
any association between pretransplant CRP and graft outcome, whereas elevated CRP
levels one month posttransplantation were strongly predictive of graft failure. In agree-
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ment with the findings of Sezer et al. (2002), Varagunam et al. (2004) showed elevated
pretransplant CRP levels to predict cardiovascular and all-cause mortality, but not graft
outcome. Elevated pretransplant CRP may be due to its decreased renal clearance, as well
(Panichi et al. 2002).
The findings of this thesis agree with those of Stuveling et al. (2003) who showed elevat-
ed CRP to indicate a risk for renal function loss in non-diabetic population, and with
those of Sezer et al. (2002) who showed increased posttransplantation CRP to indicate a
risk for CAD and are also consistent with the findings of Fink et al. (2002) who showed
that some renal transplant recipients - independent of treatment- were more likely to man-
ifest inflammation and to have elevated concentrations of CRP. They suggested that the
disposition to manifest inflammation may be a phenotypic characteristic. The results of
this study showed (Study VI), in agreement with the previous findings (Macy et al. 1997,
Ockene et al. 2001, Blake and Ridker 2002, de Ferranti and Rifai 2002, Stehouwer et al.
2002), that some patients had elevated CRP and that the intraindividual baseline concen-
trations of CRP remained relatively stable during the whole follow-up period. These find-
ings suggest that the baseline concentrations of CRP are, at least in part, determined by
genetic factors (Pankow et al. 2001, Fink et al. 2002).
CRP is induced by proinflammatory cytokines such as IL-1, IL-6, and TNF-α. The func-
tion of IL-1 is regulated by IL-1ra. The insufficient production of IL-1ra in relation to IL-
1 results in prolonged inflammation (Dinarello 2000). The finding that increased fre-
quency of allele 2 in the IL-1ra gene was observed in young, non-renal patients with high
CRP ( Manzoli et al. 1999) suggests the role of genetic factors in the regulation of CRP.
8. CRP does not accumulate in the grafts with  CAN
CRP appears to be associated - probably also causally - to the development of atheroscle-
rotic lesions (Maseri 1997, Danesh et al. 2000, Morrow and Ridker 2000, Blake and
Ridker 2001, Pepys 2001). In these lesions, CRP has been found colocalized with com-
plement and it is believed to induce tissue injury via the local activation of complement
(Lagrand et al. 1997, Torzewski et al. 1998, Griselli et al. 1999, Blake and Ridker 2001).
The certain similarities between vascular lesions in CAN and atherosclerotic lesions sug-
gest a similar pathogenesis of these disorders. Even though CRP has been found in the
kidney in glomerular disease (Nakahara et al. 2001), in diabetic nephropathy (Schwedler
et al. 2003), and in acute rejection (Jabs et al. 2003), we failed to demonstrate CRP in any
of the protocol biopsies (Study VI). The absence of CRP in biopsies of CAN was con-
firmed by Jabs et al. (2003) who demonstrated local expression and accumulation of CRP
in renal allografts with severe acute rejection but not in those with CAN.
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9. Chronic inflammation and CAD
One major new finding of this thesis is the association between chronic inflammation and
CAD. Study VI showed that during the follow-up period, concentration of CRP  in some
patients was constantly high, and that there was a correlation between CRP and the annu-
al decrease of 24-hr creatinine clearance. The latter result is consistent with the recent
finding that in patients with renal insuffiency elevated CRP correlated inversely with
GFR (Menon et al. 2003, Shlipak et al. 2003).
 During inflammation, locally produced cytokines may participate in the development of
renal damage through several mechanisms. They may cause direct cellular injuries, alter
glomerular protein barrier, or develop intrarenal inflammatory reaction. CRP can stimu-
late expression and release of TNF-α, IL-1β, and of IL-6 from monocytes and to cause the
expression of ICAM-1 and VCAM-1 by epithelial cells (Pasceri et al. 2000). Increased
amounts of IL-6 have been reported in human renal grafts developing CAD, simultane-
ously with increasing tubular atrophy, interstitial fibrosis and intimal proliferation (Nadeau
et al. 1995).
Interleukin-6, the main inducer of CRP synthesis, is produced in adipose tissue and also
in renal mesangial and proximal tubular epithelial cells. A reported positive association
between body weight and CRP suggests IL-6-induced low-grade inflammation in persons
with excess body fat (Visser et al. 1999, Yudkin et al. 1999). Recent studies have demon-
strated that serum levels of CRP and IL-6 are inversely related to insulin sensitivity in
type 1 diabetic patients (Saraheimo et al. 2003). These findings suggest that low grade
inflammation is associated with insulin resistance (IR) and that the increased concentra-
tions of IL-6 and CRP are markers of IR (Yudkin et al. 1999, Festa et al. 2000, Pradhan et
al. 2003) or that low-grade inflammation may cause IR (Saraheimo et al. 2003). The
finding that IL-6 can induce insulin resistance in mouse supports the latter assumption
(Senn et al. 2002). The findings that renal transplanted patients have higher fasting insu-
lin concentration and higher prevalence of IR than the healthy subjects (Ekstrand et al.
1992) are interesting in this regard. IR is characterized by hyperlipidemia, obesity, hyper-
tension, proteinuria, and increased risk of cardiovascular disease (Bao et al. 1996, Groop
and Orho-Melander 2001) and by increased serum levels of CRP (Marques-Vidal et al.
2002). These characteristics have been identified as risk factors for CAD. De Vries et al.
(2003) thought insulin resistance to underlie many recipient-related risk factors of CAD.
It can be concluded that low-grade inflammation causes CAD. The finding that statins
reduce the concentration of CRP (Ridker et al. 1999, Albert et al. 2001, Jialal et al. 2001)
and improve patient´s survival after renal transplantation (Cosio et al. 2002) points the
role of inflammation in the development of CAD.
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10. Strategies for the future
The aim of the current study was to develop means to detect early posttransplantation
complications and to find out  sensitive indicators of the response of the renal allograft to
injury that would predate the onset of chronic allograft nephropathy.
On the basis of the results of this study, it is concluded that the regular measurement of
urinary excretion of α1M provides a sensitive means to detect disturbances in the func-
tion or in the number of proximal tubular epithelial cells and that the excretion of PIIINP
provides a noninvasive measure of ongoing renal fibrosis. Low or decreasing urinary
α1M/creatinine and PIIINP/creatinine ratios in consequtively collected urine samples to-
gether with low serum CRP indicate good prognosis and rule out prolonged or recurrent
injury and the need for biopsy, whereas high or increasing values signal for further inves-
tigations. Biopsy of the renal transplant remains the standard procedure for establishing
the cause of dysfunction.
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SUMMARY AND CONCLUSIONS
1. Renal transplantation and prolonged cold ischemia time cause transient tubular epi-
thelial cell injury that is signalled by markedly increased urinary excretion of α1M.
Averagely one week  after transplantation, the mean urinary α1M/creatinine is ap-
proximately 50 times higher than that of the healthy persons and associates with the
duration of cold ischemia. Thereafter, the decrease of α1M/creatinine ratio in conse-
qutively collected urine samples indicates recovering tubular function and rules out
rejection, whereas the increase of this ratio indicates  acute rejection or other compli-
cations (I).
2. Patients with acute rejection have higher urinary excretion of IL-1β and lower excre-
tion of IL-1ra than patients with stable graft function. Patients who produce high
amounts of IL-1ra in relation to IL-1β are less prone to acute rejection than those with
low IL-1ra/IL-1β ratio. (II) It remains to be seen whether the detection of gene poly-
morphisms associated with productions of IL-1β or IL-1ra will help to identify pa-
tients prone to acute rejection.
3. In patients with rejections, urinary excretion of sICAM-1 increases a few days before
clinical rejection, whereas in patients with stable graft function it remains stable and
comparable to that of healthy subjects. During rejection, urinary sICAM-1 originates
from activated macrophages and from tubular epithelial cells. (III)
4. Increased urinary excretion of PIIINP associates with the extent of interstitial fibrosis
and indicates ongoing fibrotic processes in the transplanted kidney and poor long-
term graft outcome. (IV)
5. Prolonged, increased urinary excretion of α1M associates with progressive deteriora-
tion of graft function and serves as an early and sensitive indicator of poor graft
outcome. (V)
6. The close correlations found between urinary excretions of α1M and PIIINP, of α1M
and TGF-β1, and between these excretions and the deterioration of graft function
agree with the previous findings that the transformation of tubular epithelial cells to
myofibroblasts contribute to the development of CAD, and suggest that the urinary
excretions of α1M and PIIINP may serve as the measures of this transformation.
(IV, V)
7. Microalbuminuria serves as an early indicator of poor long-term graft outcome, whereas
macroalbuminuria associates with reduced renal function and is inferior to α1M as
the indicator of CAD. (V)
8. Low-grade inflammation is an important predictor of the progression of CAD. (VI)
9. CRP does not accumulate in the grafts with CAN. (VI)
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